-1 	|BT| (S (NP (NP (DT These) (NN animal)) (NP (VP (VP (VBN reduced)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (NP (JJR <) (CD 0.05))) (-RRB- -RRB-))) (NP (JJ colonic) (NN RFC1) (NN mRNA)))) (VP (VBD exhibited) (NP (JJ 2-fold) (NN reduction) (NN plasma) (NN S-adenosylmethionine/S-adenosylhomocysteine)))) |ET| |BS|19:B01.050 46:A03.556.124.526.356 111:D13.444.735.544 175:J01.897.280.500.269 232:D02.886.030.676.180 657:A12.207.152.693|ES| 10:1 14:1 19:1 46:1 311:1 312:1 325:1 370:1 452:1 609:1 677:1 792:1 2400:1 3549:1 3849:1 5266:1 5267:1
-1 	|BT| (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (S (NP (NN resveratrol)) (VP (VBP prevent) (NP (NP (NN formation) (NN growth) (JJ colorectal) (NN tumor)) (VP (VBG downregulating) (NP (NNP Kras) (NN expression))))))))) |ET| |BS|20:G03.495 45:G07.700.320.249 388:G05.360.340.024.340.375.500.791.550 1031:C04.588.274.476.411.307|ES| 7:1 17:1 19:1 43:1 102:1 115:1 733:1 792:1 793:1 1479:1 1712:1 2065:1 5142:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (SBAR (S (NP (VBN demonstrated) (NNS SK-Hep1-NIS)) (VP (MD could) (VP (ADVP (RB selectively)) (VBN killed) (NP (JJ induced) (NN 131I) (NN 188Re-perrhenate) (NN accumulation) (NN NIS) (NN gene) (NN expression)))))))) |ET| |BS|155:G05.355.310 1443:I01.198.240.470|ES| 9:1 19:1 101:1 115:1 412:1 792:1 908:1 1175:1 2120:1 3523:1 5268:1 5269:1 5270:1 5271:1 5272:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VB establish) (SBAR (S (NP (JJ mechanistic) (NN rationale) (NN Src) (NN inhibition) (NN dasatinib) (JJ therapeutic) (NN target) (NN treatment) (JJ pancreatic) (NN cancer)) (VP (VBP identify) (NP (JJ potential) (NNS biomarkers) (NN resistance) (NN Src) (NN inhibition)))))))) |ET| |BS|43:F01.145.544 52:E02 158:D23.101 1386:D02.886.675.184|ES| 18:1 19:1 101:1 103:1 160:1 220:1 467:1 541:1 546:1 792:1 827:1 832:1 1094:1 1269:1 1495:1 1890:1 3674:1 5017:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (SBAR (S (NP (VBP suggest) (NN alteration) (NN TSLC) (NN cascade)) (VP (MD might) (NP (NN role) (NN hepatocarcinogenesis)) (S (VP (VBG using) (NP (NNP DEN) (NN rat))))))))) |ET| |BS|15:F01.829.316.616 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700|ES| 19:1 31:1 101:1 350:1 792:1 796:1 798:1 849:1 900:1 951:1 1875:1 5273:1 5274:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP suggest) (SBAR (S (NP (NN SGE)) (VP (VBZ suppresses) (NP (NN induction) (NN Cyp1a1)) (, ,) (S (VP (VBG leading) (SBAR (S (NP (NN inhibition) (NN ROS) (NN generation)) (ADVP (RB consequently)) (VP (VBD inhibited) (NP (NN hepatocarcinogenesis)) (, ,) (NP (ADVP (RB probably)) (NP (JJ due) (NN suppression) (NN Ahr) (NN activity)))))))))))))) |ET| |BS|43:F01.145.544 86:D01.268.556.435 122:C14.280.383 506:F01.829.263.315 1352:D08.244.453.040.332|ES| 2:1 19:1 101:1 103:1 365:1 399:1 639:1 686:1 736:1 792:1 796:1 900:1 1787:1 2356:1 2453:1 2851:1 4415:1 5160:1 5162:1 5275:1 5276:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBN suggested) (SBAR (S (NP (JJ gestational) (JJ arsenic) (NN exposure)) (VP (VBZ induces) (SBAR (S (NP (NP (JJ tumor-augmenting) (NN change)) (, ,) (PP (VBG including) (NP (NP (JJ oxidative) (NN stress) (NN L1) (NN activation)) (, ,) (NP (JJ late-onset) (NN manner)) (, ,)))) (VP (MD would) (VP (ADVP (RB particularly)) (VB promote) (NP (JJ tumorigenic) (NN expansion) (NN cell) (NN C61A) (NN Ha-ras) (NN mutation)))))))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 18:G05.365.590 41:A11 216:Z01.107.084.900.425 716:G03.495.710 1158:D01.268.513.249 1266:G08.686.785.760.769 1444:N05.715.350.075.100|ES| 2:1 19:1 34:1 94:1 101:1 200:1 214:1 225:1 561:1 679:1 747:1 792:1 866:1 925:1 1362:1 1668:1 1809:1 1953:1 2380:1 2522:1 2583:1 3473:1 3976:1 4106:1 5277:1 5278:1 5279:1
-1 	|BT| (S (NP (DT This) (JJ toxicogenomic) (NN analysis)) (VP (VBD revealed) (NP (NP (JJ several) (JJ aberrant) (NN gene) (NN expression) (NN change)) (VP (VBN associated) (NP (JJ transplacental) (JJ arsenic) (NN carcinogenesis)))))) |ET| |BS|33:C04.697.098 155:G05.355.310 1158:D01.268.513.249|ES| 9:1 19:1 115:1 169:1 200:1 207:1 262:1 275:1 661:1 807:1 1725:1 4106:1 5280:1 5281:1
-1 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (CD 1,25) (NN D) (NN VDR)) (VP (VBP regulate) (NP (NN c-MYC/MXD1) (NN network)) (VP (VBP suppress) (NP (NN c-MYC) (NN function)) (, ,) (S (VP (VBG providing) (NP (JJ molecular) (NN basis) (NN cancer) (JJ preventive) (NN action) (NN vitamin) (NN D))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 588:I01.880.853.500.600 720:D04.808.247.222.474 721:D04.808.812.768|ES| 2:1 18:1 19:1 33:1 161:1 625:1 858:1 1140:1 1691:1 1883:1 2013:1 2154:1 2441:1 2591:1 2592:1 3025:1 4529:1 5129:1 5282:1
-1 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (JJ final) (NN death) (NN outcome) (JJ 5-FU-treated) (NN p53)) (: -) (: /) (: -) (NP (NP (NN cell) (VBD demonstrated) (ADJP (ADJP (JJ caspase-dependent)) (, ,) (ADJP (JJ due) (JJ slow))) (NN pace)) (, ,) (NP (NN accumulation) (JJ mitochondrial) (JJ reactive) (NN oxygen) (NN specie))) (VP (VBZ contributes) (NP (JJ necrotic) (NN characteristic)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 52:E02 134:G04.299.139 135:C23.550.260 560:D03.383.742.698.875.404 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 636:D01.339.431 1216:C23.550.717 1367:D08.811.277.656.262.500.126 1445:D08.811.277.656.300.760.353|ES| 2:1 19:1 94:1 336:1 411:1 547:1 845:1 1175:1 1505:1 1691:1 2004:1 2120:1 2353:1 2354:1 2355:1 2851:1 5283:1 5284:1 5285:1 5286:1 5287:1 5288:1
-1 	|BT| (NP (NP (NP (NP (NNP Thymidylate) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NN TS)) (-RRB- -RRB-))) (NP (NP (NP (NN overexpression) (JJ key) (NN determinant) (NN 5-fluorouracil)) (PRN (-LRB- -LRB-) (NP (NN 5-FU)) (-RRB- -RRB-))) (NP (NN resistance) (JJ human) (NN cancer) (NN cell))))) |ET| |BS|41:A11 55:B01.050.150.900.649.801.400.112.400.400 560:D03.383.742.698.875.404 713:D08.811.913.555.500.862|ES| 10:1 14:1 18:1 19:1 36:1 66:1 94:1 152:1 159:1 509:1 1094:1 2307:1 2308:1 3081:1 4359:1
-1 	|BT| (S (S (VP (TO To) (VP (VB examine) (NP (NP (JJ possible) (JJ direct) (JJ transcriptional) (NN regulation)) (NP (NN rat) (NN Bcl-2) (NN beta-catenin/Tcf)))))) (, ,) (VP (VBN cloned) (VP (VBN characterized) (SBAR (S (NP (JJ corresponding) (NN promoter) (NN region)) (VP (VBD found) (NP (NP (ADJP (CD 70.1) (NN %)) (NN similarity) (JJ human) (NN counterpart)) (, ,) (NP (NN BCL2))))))))) |ET| |BS|23:D12.776.091.249 30:Z01.058.290.190.800 31:D08.811.520.224.800 54:G05.360.340.024.340.375.500.791.150 55:B01.050.150.900.649.801.400.112.400.400 142:I01.880.604 196:G02.111.570.080.689.675 209:G02.111.087.847 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 301:A11.251.353|ES| 2:1 19:1 36:1 37:1 83:1 158:1 369:1 438:1 559:1 667:1 828:1 849:1 960:1 985:1 1048:1 1359:1 1891:1 3526:1 4231:1 4999:1 5289:1 5290:1 5291:1
-1 	|BT| (S (VP (ADVP (RB Together)) (, ,) (VBG finding) (VP (VBP suggest) (SBAR (S (NP (NN silibinin)) (VP (VBZ inhibits) (NP (NP (NN growth) (NN SW480) (NN tumor)) (VP (VBG carrying) (NP (JJ mutant) (NN APC) (NN gene) (NN down-regulating) (NN CDK8) (NN beta-catenin) (NN signaling)))) (, ,) (ADVP (RB therefore)) (, ,) (VP (MD could) (NP (JJ effective) (NN agent) (NN CRC))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 12:Z01.542.049 21:G05.360.340.024.340.375.249.050 23:D12.776.091.249 45:G07.700.320.249 69:G02.111.087.800 122:C14.280.383 247:G01.374.676.530 351:A17.360|ES| 2:1 7:1 9:1 11:1 19:1 60:1 102:1 195:1 218:1 245:1 615:1 728:1 796:1 811:1 850:1 908:1 927:1 1639:1 2635:1 3095:1 3096:1 3097:1 3098:1
-1 	|BT| (S (NP (NN TOPflash) (NN luciferase) (NN reporter) (NN assay)) (VP (VBD showed) (S (NP (NP (JJ transcriptional) (NN activity) (NN T-cell) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN TCF)) (-RRB- -RRB-))) (ADJP (: /) (SBAR (S (NP (JJ lymphoid) (NN enhancer) (NN factor) (-LRB- -LRB-) (NN LEF) (-RRB- -RRB-)) (VP (VBD reduced) (SBAR (S (NP (NP (NN NDRG2) (NN introduction)) (, ,) (NP (NN introduction) (JJ mutant) (NN NDRG2))) (VP (VBD generated) (NP (NN deletion) (JJ site-directed) (NN mutagenesis)))))))))))) |ET| |BS|106:E05.091 209:G02.111.087.847 306:G05.355.600.800 1375:D08.811.682.517 1446:A11.118.637.555.567 1447:E05.393.420.601.575|ES| 2:1 10:1 14:1 19:1 73:1 132:1 185:1 288:1 310:1 399:1 452:1 559:1 811:1 972:1 1059:1 4864:1 4952:1 4963:1 5210:1 5292:1 5293:1 5294:1 5295:1 5296:1 5297:1
-1 	|BT| (S (NP (NN Toxaphene)) (VP (VBD induced) (NP (NP (JJ significant) (NP (NP (NN increase) (NN expression) (JJ constitutive) (NN androstane) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN CAR)) (-RRB- -RRB-))) (NN target) (NN gene)) (PRN (-LRB- -LRB-) (NP (NP (NN Cyp2b10)) (, ,) (NP (NN Cyp3a11))) (-RRB- -RRB-))) (NP (QP (CD 32) (CD 320)) (NN ppm) (NN toxaphene)))) |ET| |BS|6:G05.360.340.024.340 1149:D02.455.526.439.913|ES| 2:1 9:1 10:1 14:1 19:1 40:1 115:1 135:1 160:1 186:1 412:1 421:1 604:1 605:1 2546:1 3233:1 3985:1 4164:1 4299:1 5298:1 5299:1
-1 	|BT| (S (NP (NN Treatment) (NN HepG2) (NN cell) (NN APAP)) (ADVP (RB significantly)) (VP (VBD reduced) (NP (NN expression) (NN DAX-1) (JJ concentration-dependent) (NN manner)))) |ET| |BS|52:E02 661:D02.065.199.092.040 905:F02.830.104.214 1015:A11.251.860.180.432|ES| 19:1 94:1 115:1 124:1 452:1 1668:1 3106:1 3481:1 4193:1 4537:1 5300:1
-1 	|BT| (NP (NP (NN Treatment) (NP (NP (NN rat) (NN DHEA) (NN influence) (NN expression) (NN cytochrome) (NN P450)) (PRN (-LRB- -LRB-) (NP (NN P450)) (-RRB- -RRB-))) (NN gene)) (, ,) (FRAG (VBG including) (NP (NN peroxisome) (JJ proliferator-activated) (NN receptor) (NN alpha)) (-LRB- -LRB-) (NP (NP (NP (NP (NN PPAR) (NN alpha) (-RRB- -RRB-)) (: -) (NP (NP (NN pregnane) (NN X) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN PXR)) (-RRB- -RRB-)))) (: -) (NP (VBN mediated) (NN induction) (NNS CYP4As) (NN CYP3A23)) (, ,) (NP (NN suppression) (NN CYP2C11)))))) |ET| |BS|6:G05.360.340.024.340 52:E02 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 536:D12.776.826.239.500 740:D04.808.054.079.429.625 1079:D08.244.453 1448:D08.244.453.450|ES| 2:1 9:1 10:1 14:1 19:1 115:1 186:1 561:1 736:1 849:1 867:1 929:1 1801:1 1836:1 1887:1 2453:1 2549:1 2633:1 2691:1 3106:1 3227:1 3788:1 4048:1 4899:1 5301:1 5302:1 5303:1 5304:1
-1 	|BT| (S (NP (NN Treatment) (NN cell) (NN oxazepam) (CD 48) (NN h)) (ADVP (RB also)) (VP (VBD resulted) (SBAR (S (NP (VBN decreased) (NN Tsc-22)) (VP (VBD increased) (NP (NN Gadd45b) (NN expression))))))) |ET| |BS|41:A11 52:E02 179:D01.248.497.300.459.700 1329:D03.438.079.080.070.663|ES| 5:1 19:1 47:1 94:1 115:1 202:1 594:1 3106:1 4741:1 4855:1 5180:1 5305:1 5306:1
-1 	|BT| (S (NP (NN Treatment) (NN 5-AzaC)) (ADVP (RB concomitantly)) (NP (VBN upregulated) (NN expression) (NN miR-9-3) (NN miR-193a)) (, ,) (VP (VBD downregulated) (NP (JJ respective) (NN target) (NN gene) (NN NF-kappaB) (NN Mcl-1)))) |ET| |BS|6:G05.360.340.024.340 52:E02 210:D12.776.260.600|ES| 2:1 9:1 19:1 115:1 125:1 160:1 426:1 714:1 3106:1 5307:1 5308:1 5309:1 5310:1 5311:1 5312:1
-1 	|BT| (S (NP (NN Troglitazone)) (VP (VBZ induces) (NP (JJ p27Kip1-associated) (NP (JJ cell-cycle) (NN arrest) (JJ down-regulating) (NN Skp2) (JJ human) (NN hepatoma) (NN cell))))) |ET| |BS|41:A11 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 338:D12.644.360.225.600 351:A17.360 507:D12.776.157.743 515:C04.588.274.623 773:G04.299.134.109|ES| 19:1 36:1 94:1 214:1 602:1 1785:1 3097:1 3116:1 3896:1 5313:1 5314:1
-1 	|BT| (S (NP (NN Troglitazone)) (ADVP (RB potently)) (VP (VBD inhibited) (SBAR (S (NP (NN proteasome) (NN activity)) (VP (VBD decreased) (NP (NN Skp2) (NN protein) (NN level))))))) |ET| |BS|122:C14.280.383 507:D12.776.157.743 1281:D05.500.562.500|ES| 4:1 19:1 202:1 249:1 365:1 399:1 1785:1 3116:1 3128:1 4559:1
-1 	|BT| (S (NP (NN TS)) (ADVP (RB also)) (VP (ADVP (RB acutely)) (VBN up-regulated) (NP (NP (NN 5-FU) (NN treatment)) (, ,) (, ,) (ADVP (RB thus)) (, ,) (NP (NP (JJ novel) (NN strategy)) (VP (VBG targeting) (NP (NN TS) (NN down-regulation))))) (VP (VBP seem) (NP (JJ promising) (NN term) (VBG modulating) (NN 5-FU) (NN resistance))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 85:G02.111.087.225 142:I01.880.604 150:Z01.542.248.960 154:Z01.058.266.887 259:D12.776.395.240.150.500 560:D03.383.742.698.875.404 849:G08.686.785.760.769.490.500|ES| 2:1 5:1 19:1 257:1 509:1 546:1 616:1 891:1 995:1 1094:1 1114:1 1301:1 1334:1 1517:1 2308:1 2435:1 5315:1 5316:1
-1 	|BT| (NP (NP (NP (NN Upregulation) (NN B-cell) (NN translocation) (NN gene) (CD 2) (JJ epigallocatechin-3-gallate)) (PP (IN via) (NP (NN p38) (NN ERK) (NN signaling) (NN block) (NN cell) (NN proliferation) (JJ human) (JJ oral) (JJ squamous) (NN cell) (NN carcinoma) (NN cell))))) |ET| |BS|6:G05.360.340.024.340 38:Z01.058.290.120.180 40:Z01.542.248.700 41:A11 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 122:C14.280.383 183:G04.299.233.750 249:G05.355.315.800 310:A11.063.438 339:G02.111.087.880 463:C23.550.210.870 929:C04.557.470.200.400|ES| 9:1 19:1 36:1 94:1 148:1 195:1 299:1 304:1 596:1 742:1 1067:1 1618:1 1666:1 2199:1 2629:1 5047:1 5317:1 5318:1
-1 	|BT| (S (NP (JJ Ursodeoxycholic) (NN acid)) (VP (VBZ inhibits) (NP (NP (NN Ras) (NN mutation)) (, ,) (NP (NP (JJ wild-type) (NN Ras)) (NN activation)) (, ,) (NP (NN cyclooxygenase-2) (NN expression) (NN colon) (NN cancer))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 24:D08.811.600.720.750 122:C14.280.383 737:D04.808.105.225.272.962|ES| 2:1 8:1 18:1 19:1 34:1 61:1 113:1 115:1 225:1 615:1 1275:1 1775:1 3121:1
-1 	|BT| (S (S (VP (VBG Using) (NP (NN xenograft) (ADJP (NN tumor) (NN model) (JJ severe)) (JJ combined) (JJ immune) (NN deficiency) (NN mouse)))) (, ,) (VP (MD could) (VP (VB show) (SBAR (S (NP (NP (JJ experimental) (JJ systemic) (NN hypergastrinemia)) (VP (VBD induced) (NP (NN administration) (NN omeprazole)))) (VP (VBD led) (NP (VBN enhanced) (NN apoptosis)) (ADVP (RB well)) (NP (NP (JJ marked) (NN increase) (NN IEX-1) (NN expression) (NN Colo320wt) (NN tumor)) (, ,) (NP (NN Colo320mut) (NN tumor))))))))) |ET| |BS|8:C04 39:G04.299.139.160 86:D01.268.556.435 92:E04.936.764 93:A01.941.875 984:D02.886.640.074.500 1449:B01.050.150.900.649.865.635.505.500.550.780|ES| 2:1 7:1 19:1 40:1 52:1 72:1 89:1 115:1 164:1 253:1 263:1 265:1 385:1 412:1 429:1 760:1 787:1 908:1 1719:1 2228:1 2575:1 2802:1 3169:1 3467:1 4693:1 5037:1 5044:1 5319:1 5320:1
-1 	|BT| (S (S (VP (VBG Using) (NP (JJ several) (JJ experimental) (NN approach)))) (, ,) (VP (VBP conclude) (SBAR (S (NP (JJ RNA-rather) (JJ DNA-related) (NN stress)) (VP (VBZ follows) (NP (NP (NN caspase) (NN activation)) (RRC (ADVP (RB irrespectively)) (NP (NN p53) (NN status))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 198:D13.444.308 557:D02.241.081.069.600.150 1367:D08.811.277.656.262.500.126 1422:D13.444.735|ES| 2:1 12:1 19:1 225:1 262:1 263:1 416:1 911:1 1719:1 1968:1 2522:1 4796:1 5321:1 5322:1 5323:1 5324:1
-1 	|BT| (S (NP (NN UV) (NN exposure)) (VP (VBP result) (NP (NP (NP (JJ ligand-independent) (NN activation) (JJ epidermal) (NN growth) (NN factor) (NN receptor) (JJ subsequent) (NN activation)) (JJ mitogen-activated) (NN protein) (NN kinase) (NN phosphatidylinositol) (NN 3-kinase/Akt) (NN pathway)) (VP (VBG leading) (NP (JJ transcriptional) (NN activation) (NN COX-2) (NN gene)))))) |ET| |BS|6:G05.360.340.024.340 64:D08.811.913.696.620.682.725.400.009.300 86:D01.268.556.435 170:D27.720.470.480 209:G02.111.087.847 249:G05.355.315.800 264:G05.355.315.800 378:D08.811.913.696.620.682.700.755 478:D08.811.913.696.620.682.700.567 1377:D08.811.913.696.620.500.100 1450:G01.358.500.505.650.891 1451:Z01.058.290.190.245|ES| 4:1 9:1 19:1 76:1 101:1 102:1 184:1 185:1 186:1 225:1 383:1 470:1 559:1 639:1 1319:1 1953:1 2081:1 3295:1 4969:1 5325:1 5326:1
-1 	|BT| (S (NP (NN Vitamin) (NN D)) (VP (VBZ Enhances) (NP (NNP Efficacy) (NNP Irinotecan) (JJ miR-627-Mediated) (NN Inhibition) (NNP Intratumoral) (NNP Drug) (NNP Metabolism)))) |ET| |BS|43:F01.145.544 67:D26 720:D04.808.247.222.474 721:D04.808.812.768 898:G03.495|ES| 19:1 2345:1 2592:1 2703:1 3665:1 4953:1 5327:1 5328:1 5329:1 5330:1 5331:1
-1 	|BT| (S (NP (NN Vitamin) (NN D) (NN signaling)) (VP (VBP suppress) (NP (NP (NN expression) (NN gene) (VBN regulated) (NN c-MYC)) (, ,) (NP (NP (NP (NN transcription) (NN factor) (NN control)) (JJ epidermal) (NN differentiation) (NN cell) (NN proliferation)) (SBAR (WHNP (WP$ whose) (NN activity)) (S (VP (ADVP (RB frequently)) (JJ elevated) (NP (NN cancer))))))))) |ET| |BS|69:G02.111.087.800 74:G04.299.151 142:I01.880.604 155:G05.355.310 166:D12.776.930 183:G04.299.233.750 720:D04.808.247.222.474 721:D04.808.812.768 1095:A10.272.497|ES| 2:1 9:1 18:1 19:1 94:1 115:1 184:1 185:1 195:1 215:1 289:1 299:1 399:1 487:1 625:1 698:1 756:1 919:1 1664:1 2441:1 2592:1 3665:1
-1 	|BT| (S (NP (NN Vitamin) (NN E) (NN succinate)) (VP (VBZ induces) (NP (NN NAG-1) (NN expression) (NN p38) (JJ kinase-dependent) (NN mechanism)))) |ET| |BS|469:D08.811.913.696 1452:D03.383.663.283.909.750.249|ES| 19:1 115:1 162:1 214:1 1662:1 1666:1 1667:1 2085:1 3665:1 5332:1
-1 	|BT| (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD observed) (SBAR (S (NP (NN flavokawain) (NN B)) (VP (VBD caused) (NP (NP (NP (NN G2/M) (NN phase) (NN arrest) (JJ mediated) (NN reduction) (NN level) (NN cyclin) (NN A)) (, ,) (NP (NN cyclin) (NN B1))) (, ,) (NP (NN Cdc2) (NN Cdc25C) (NN increase) (NN p21/WAF1)) (, ,) (NP (NN Wee1) (NN p53) (NN level)))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 122:C14.280.383 979:D12.644.360.262.120.100 1431:D12.644.360.262.100 1453:G04.299.134.500.340|ES| 2:1 5:1 12:1 19:1 40:1 69:1 249:1 261:1 370:1 437:1 602:1 743:1 763:1 843:1 2506:1 2528:1 2529:1 3455:1 5333:1 5334:1 5335:1 5336:1 5337:1
-1 	|BT| (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD demonstrated) (S (NP (NP (NN FOXM1)) (PRN (-LRB- -LRB-) (NP (NN 1B) (NN 1C) (NNS isoforms)) (-RRB- -RRB-))) (ADVP (RB directly)) (VP (VBP bind) (ADVP (RB transcriptionally)) (VP (VBZ regulates) (NP (NP (NP (NN eEF2K) (NN gene) (NN expression) (NN chromatin) (NN immunoprecipitation)) (PRN (-LRB- -LRB-) (NP (NN ChIP)) (-RRB- -RRB-))) (NN luciferase) (NN gene) (NN reporter) (NN assay))))))) |ET| |BS|6:G05.360.340.024.340 106:E05.091 155:G05.355.310 238:D12.776.800 1375:D08.811.682.517 1454:E05.393.170|ES| 5:1 9:1 10:1 14:1 19:1 115:1 288:1 310:1 603:1 621:1 821:1 843:1 1175:1 1346:1 1854:1 4857:1 4963:1 5100:1 5338:1 5339:1 5340:1 5341:1 5342:1
-1 	|BT| (S (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD found) (SBAR (S (NP (NN pectolinarigenin)) (ADVP (RB significantly)) (VP (VBD suppressed) (NP (NN osteosarcoma) (NN cell) (NN proliferation))))))) (, ,) (VP (VBD induced) (NP (NP (NP (NP (NP (NN apoptosis)) (VP (VBN reduced) (NP (NN level) (NN STAT3) (JJ downstream) (NN protein) (NN cyclin) (NN D1)))) (, ,) (NP (NN Survivin)) (, ,)) (NP (NP (NN B-cell) (NN lymphoma) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN Bcl-2)) (-RRB- -RRB-)))) (, ,) (NP (NP (NP (NN B-cell) (NN lymphoma) (NN extra-large)) (PRN (-LRB- -LRB-) (NP (NN Bcl-xl)) (-RRB- -RRB-))) (NP (NP (JJ myeloid) (NN cell) (NN leukemia) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN Mcl-1)) (-RRB- -RRB-))))))) |ET| |BS|39:G04.299.139.160 41:A11 82:D12.644.360.024.342.300 183:G04.299.233.750 215:D12.644.360.262.150.100 361:C04.557.337 447:C04.557.450.565.575.650 1424:C04.557.386.480.150 1455:A11.148.378.590 1456:C04.557.337.539 1457:A11.627|ES| 2:1 4:1 5:1 10:1 14:1 19:1 37:1 89:1 94:1 98:1 124:1 148:1 158:1 249:1 251:1 299:1 307:1 412:1 452:1 560:1 591:1 743:1 744:1 843:1 1562:1 2199:1 2785:1 3779:1 5187:1 5312:1 5343:1 5344:1 5345:1
-1 	|BT| (FRAG (NP (PRP We)) (VBD characterized) (SBAR (S (NP (NP (NN effect) (JJ gefitinib) (NN EGFR)) (, ,) (NP (NN HER2)) (, ,) (NP (NN ErbB-3) (NN phosphorylation) (NN Western) (NN blot))) (VP (VBD determined) (NP (NN effect) (JJ downstream) (NN signaling) (NN growth))))) (, ,) (NP (NP (NN survival)) (, ,) (NP (NN stress) (NN pathway) (NN effect) (NN proliferation)) (, ,) (NP (NN cell) (NN cycle)) (, ,) (NP (NN apoptosis)))) |ET| |BS|39:G04.299.139.160 45:G07.700.320.249 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 69:G02.111.087.800 96:I03.784 255:E05.196.401.143 256:E05.196.401.143 353:G04.299.134 972:G02.111.087.677 1350:G05.360.340.024.340.375.500.791.295|ES| 2:1 19:1 75:1 89:1 94:1 102:1 187:1 188:1 195:1 274:1 299:1 383:1 560:1 601:1 843:1 872:1 873:1 985:1 1582:1 2522:1 3310:1 3426:1 4818:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD found) (NP (NP (NP (CD 7) (RB differentially) (VBN expressed) (NN gene)) (, ,) (NP (NN cyclin) (NN D1))) (, ,) (NP (NP (NN cyclin) (NN E)) (, ,) (NP (NN c-myc)) (, ,) (NP (NN Fosl1)) (, ,) (NP (NN c-fos)) (, ,) (NP (NN Cd44) (NN follistatin)) (, ,) (NP (NP (VBN known) (NN target) (NN beta-catenin)) (CC and/or) (NP (NN ra))) (NP (NN pathway)))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 6:G05.360.340.024.340 23:D12.776.091.249 165:G05.360.340.024.340.375.500.791.330 215:D12.644.360.262.150.100 1366:D12.776.260.108.765 1458:D12.644.360.262.180 1459:D12.776.157.247|ES| 2:1 6:1 9:1 19:1 37:1 60:1 149:1 160:1 383:1 455:1 556:1 562:1 743:1 744:1 843:1 988:1 1115:1 1139:1 2085:1 5346:1 5347:1 5348:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD found) (NP (NP (NN Tsc-22) (NN downregulation) (NN liver) (NN B6C3F1) (NN mouse)) (PP (VBG following) (NP (NP (NN treatment) (CD 2) (NN week)) (NP (NP (NP (JJ carcinogenic) (NNS dos) (JJ antianxiety) (NN drug) (NN oxazepam)) (PRN (-LRB- -LRB-) (NP (CD 2500) (NN ppm)) (-RRB- -RRB-))) (NP (NP (NP (NN peroxisome) (NN proliferator) (NN Wyeth-14,643)) (PRN (-LRB- -LRB-) (NP (CD 500) (NN ppm)) (-RRB- -RRB-))) (NP (NP (CD two) (NN carcinogen) (NN o-nitrotoluene) (NN methyleugenol) (CD three) (NNS noncarcinogens)) (PP (VBG including) (NP (NP (NN p-nitrotoluene)) (, ,) (NP (NN eugenol)) (, ,) (NP (NN acetaminophen)))))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 52:E02 85:G02.111.087.225 242:A03.620 279:D27.888.569.100 661:D02.065.199.092.040 912:D27.888.569.100.675 1165:D02.241.223.200.054.500 1329:D03.438.079.080.070.663 1460:D27.505.696.277.950.015|ES| 2:1 10:1 14:1 19:1 37:1 52:1 148:1 191:1 482:1 546:1 561:1 595:1 783:1 836:1 843:1 933:1 1887:1 1888:1 2125:1 2412:1 2653:1 3233:1 3346:1 3510:1 3986:1 4023:1 4293:1 4417:1 4741:1 5180:1 5349:1 5350:1 5351:1 5352:1 5353:1 5354:1
-1 	|BT| (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD reported) (SBAR (S (NP (NN TCE)) (VP (VBD decreased) (SBAR (S (NP (NN methylation) (NN c-jun) (NN c-myc) (NN gene)) (VP (VBD increased) (NP (NN level) (NNS mRNAs)))))))))) |ET| |BS|36:G02.111.087.029.538 111:D13.444.735.544 186:G05.360.340.024.340.375.500.791.420|ES| 9:1 19:1 47:1 81:1 202:1 249:1 447:1 455:1 843:1 993:1 1527:1 5355:1 5356:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD hypothesized) (SBAR (S (NP (JJ novel) (NN class) (NN oligoamine) (NN analogue)) (VP (MD would) (VP (ADVP (RB effectively)) (VB inhibit) (NP (NN LSD1)) (RB thus) (VP (VBP cause) (S (NP (NN reexpression)) (VP (ADVP (RB aberrantly)) (NP (VBN silenced) (NN gene))))))))))) |ET| |BS|6:G05.360.340.024.340 122:C14.280.383 259:D12.776.395.240.150.500|ES| 9:1 19:1 843:1 866:1 891:1 1334:1 1370:1 1380:1 1750:1 1779:1 2656:1 2657:1 2658:1 2814:1 2977:1 5062:1 5357:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (NN function) (NN vitamin) (JJ D-regulated) (NN miR-627) (JJ intratumoral) (NN CYP3A4) (NN suppression) (NN role)) (VP (VBG enhancing) (NP (NN efficacy) (NN chemotherapy)))))) |ET| |BS|15:F01.829.316.616 142:I01.880.604 151:E02.319 720:D04.808.247.222.474 721:D04.808.812.768 1348:D08.244.453.400|ES| 19:1 31:1 33:1 403:1 495:1 843:1 2304:1 2453:1 2527:1 2591:1 4804:1 4805:1 5358:1 5359:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (JJ anti-glioblastoma) (NN response) (NN celecoxib)) (JJ p53-dependent) (, ,) (SBAR (IN whether) (FRAG (NP (NP (ADJP (NN celecoxib) (VBD induced)) (NN DNA) (NN damage)) (VP (VBG leading) (NP (JJ p53-dependent) (NN G1) (NN cell) (NN cycle) (NN arrest)))))) (, ,) (VP (VBD followed) (NP (JJ autophagy) (NN apoptosis))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 86:D01.268.556.435 390:G04.299.139.399 526:G05.355.180 592:C04.557.465.625.600.380.080.335 684:D02.065.884.247 1076:G04.299.134.109.249|ES| 2:1 19:1 88:1 89:1 94:1 221:1 403:1 412:1 494:1 601:1 602:1 639:1 666:1 670:1 843:1 1317:1 1848:1 2807:1 3130:1 5360:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD observed) (NP (NP (NP (ADJP (NP (NN induction) (NN G)) (-LRB- -LRB-) (CD 1) (-RRB- -RRB-) (: -)) (NN S-phase) (NN arrest) (JJ caspase-mediated) (NN apoptosis)) (NP (JJ androgen-dependent) (NP (JJ human) (NN LNCaP) (NN cell)))) (, ,) (S (VP (VBP express) (NP (JJ wild-type) (NN p53))) (, ,) (NP (JJ androgen-independent) (, ,) (NP (JJ p53-mutant) (NN DU145) (NN cell))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 41:A11 55:B01.050.150.900.649.801.400.112.400.400 122:C14.280.383 892:D27.505.696.399.472.161 1367:D08.811.277.656.262.500.126|ES| 2:1 8:1 10:1 12:1 14:1 19:1 36:1 89:1 94:1 98:1 208:1 261:1 602:1 736:1 843:1 2691:1 3423:1 3520:1 4880:1 4904:1 4905:1 4925:1 5099:1 5361:1
-1 	|BT| (S (NP (PRP We)) (VP (VBP provide) (NP (NN evidence) (NN HDACi) (NN treatment) (NN lead) (JJ potent) (JJ transcriptional) (NN repression) (NN TS) (NN gene)))) |ET| |BS|6:G05.360.340.024.340 52:E02 86:D01.268.556.435 154:Z01.058.266.887 208:F01.393.821 209:G02.111.087.847|ES| 9:1 19:1 22:1 38:1 254:1 505:1 509:1 546:1 559:1 706:1 711:1 843:1
-1 	|BT| (S (NP (PRP We)) (VP (VBP show) (ADVP (RB herein)) (NP (NN induction) (NP (NP (NN tumor) (NN suppressor) (NN gene) (JJ COOH-terminal) (NN Src) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NN Csk)) (-RRB- -RRB-))) (NN NSAID) (JJ important) (JJ antiproliferative) (RB hence) (JJ chemopreventive) (NN effect)))) |ET| |BS|206:G05.360.340.024.340.375.249 469:D08.811.913.696 487:G05.355.315.800 624:D27.505.696.706.018 796:D27.505.696.663.850.014.040.500|ES| 7:1 9:1 10:1 14:1 19:1 75:1 429:1 470:1 700:1 736:1 843:1 902:1 1736:1 1946:1 3120:1 3674:1 4230:1 4499:1 5362:1 5363:1
-1 	|BT| (S (NP (PRP We)) (VP (VBP show) (SBAR (S (NP (JJ individual) (JJ homozygous) (JJ minor) (NN ODC) (NN A-allele)) (VP (VBD reported) (S (VP (VBG using) (NP (NN aspirin)) (NP (NP (QP (RB approximately) (CD 0.10)) (NN time)) (NP (NP (JJ likely) (NN adenoma) (NN recurrence) (JJ non-aspirin) (NN user)) (NP (JJ homozygous) (JJ major) (NN G-allele))))))))))) |ET| |BS|12:Z01.542.049 17:C04.557.470.035 30:Z01.058.290.190.800 31:D08.811.520.224.800 77:G05.360.340.024.340.030 322:G01.910 493:M01 496:C23.550.291.937 670:D02.455.426.559.389.657.410.595.176 1108:M01.416 1283:G05.380.554 1461:E05.318.740.600|ES| 19:1 42:1 350:1 429:1 462:1 843:1 993:1 1081:1 1328:1 1843:1 2487:1 2512:1 2697:1 3881:1 4564:1 5364:1 5365:1 5366:1 5367:1 5368:1 5369:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD showed) (SBAR (S (ADJP (RB previously) (JJ S-trans)) (, ,) (NP (NP (JJ trans-farnesylthiosalicylic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN FTS)) (-RRB- -RRB-))) (VP (VBZ disrupts) (SBAR (S (NP (NN Ras) (NN membrane) (NN anchorage) (NN disturbance)) (VP (VBZ contributes) (NP (NN inhibition) (NN cell) (NN transformation) (NN tumor) (NN growth)))))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 41:A11 43:F01.145.544 45:G07.700.320.249 1344:A10.615|ES| 2:1 7:1 10:1 14:1 19:1 94:1 102:1 103:1 132:1 843:1 845:1 1275:1 1384:1 1527:1 1775:1 3622:1 4549:1 4551:1 5253:1 5370:1 5371:1 5372:1
-1 	|BT| (NP (NP (NP (NN YGK)) (NP (ADVP (RB significantly)) (VBD repressed) (NP (NN E6/E7) (NN oncogene) (JJ transcriptional) (NN level)) (, ,) (NP (NP (JJ subsequent) (NN reactivation) (NN p53) (NN p21) (NN expression)) (PRN (-LRB- -LRB-) (NP (NP (NN P)) (ADJP (JJR <) (NP (CD 0.01)))) (-RRB- -RRB-)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 9:G05.360.340.024.340.375.500 208:F01.393.821 209:G02.111.087.847|ES| 2:1 10:1 12:1 14:1 19:1 24:1 115:1 124:1 249:1 311:1 312:1 315:1 466:1 559:1 1135:1 1319:1 1913:1 5373:1 5374:1
-1 	|BT| (S (NP (JJ Other) (NN expression) (NN alteration)) (VP (VBN observed) (S (NP (JJ arsenic-treated) (JJ male) (NN mouse) (JJ newborn) (NN liver)) (VP (VBD included) (SBAR (S (NP (NP (NN overexpression) (NNS cdk-inhibitors) (NN stress) (NN response) (NN gene)) (PP (VBG including) (NP (VBN increased) (NN expression) (NN metallothionein-1)))) (VP (VBD decreased) (NP (NN expression) (NN betaine-homocysteine) (NN methyltransferase) (NN thioether) (NN S-methyltransferase))))))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 52:E02 242:A03.620 978:D08.811.913.696.620.682.700.646.500 1158:D01.268.513.249 1462:D08.811.913.555.500.175 1463:D08.811.913.555.500 1464:D01.248.497.158.874 1465:M01.060.703.520 1466:D12.776.556.670|ES| 9:1 19:1 47:1 52:1 115:1 152:1 202:1 261:1 494:1 561:1 836:1 951:1 1402:1 1528:1 2522:1 2655:1 5375:1 5376:1 5377:1 5378:1 5379:1 5380:1 5381:1 5382:1
-1 	|BT| (S (NP (DT A) (JJ recent) (NN study)) (VP (VBD revealed) (SBAR (S (NP (NP (JJ long-term) (NN exposure)) (ADJP (RB relatively) (JJ low-dose)) (NN DEHP) (PRN (-LRB- -LRB-) (NP (CD 0.05) (NN %)) (-RRB- -RRB-))) (VP (VBD caused) (NP (NP (NN liver) (NN tumor)) (PP (VBG including) (NP (NP (JJ hepatocellular) (NN carcinoma)) (, ,) (NP (JJ hepatocellular) (NN adenoma)) (, ,) (NP (NP (NP (NP (ADJP (NP (JJ chologiocellular) (NN carcinoma)) (JJR higher)) (NN incidence) (NN Ppar) (JJ alpha-null) (NN mouse)) (PRN (-LRB- -LRB-) (NP (CD 25.8) (NN %)) (-RRB- -RRB-))) (NP (JJ wild-type) (NN mouse))) (PRN (-LRB- -LRB-) (NP (CD 10.0) (NN %)) (-RRB- -RRB-))))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 29:B01.050.050.136.500.500 104:C04.557.470.200.025.255 265:C04.557.470.200 434:E05.318.308.985.525.375 515:C04.588.274.623 536:D12.776.826.239.500 849:G08.686.785.760.769.490.500 911:D02.241.223.805.250 1194:C04.557.470.035.120|ES| 2:1 7:1 8:1 10:1 14:1 19:1 42:1 52:1 69:1 131:1 170:1 275:1 303:1 304:1 369:1 561:1 659:1 836:1 1511:1 1953:1 2506:1 3049:1 3205:1 3546:1 3849:1 3924:1 5383:1 5384:1 5385:1 5386:1 5387:1
-1 	|BT| (S (NP (NP (NN Activation) (JJ nonsteroidal) (JJ anti-inflammatory) (JJ drug-activated) (NN gene-1)) (PP (IN via) (NP (JJ extracellular) (JJ signal-regulated) (NN kinase) (CD 1/2) (JJ mitogen-activated) (NN protein) (NN kinase)))) (VP (VBD revealed) (NP (JJ isochaihulactone-triggered) (JJ apoptotic) (NN pathway) (NP (JJ human) (NN lung) (NN cancer) (NN A549) (NN cell))))) |ET| |BS|39:G04.299.139.160 41:A11 55:B01.050.150.900.649.801.400.112.400.400 264:G05.355.315.800 469:D08.811.913.696 477:D08.811.913.696.620.682.700.567.249 573:N05.715.350.200.650 796:D27.505.696.663.850.014.040.500|ES| 4:1 18:1 19:1 36:1 87:1 94:1 275:1 328:1 364:1 383:1 470:1 596:1 1707:1 1859:1 2223:1 2795:1 3046:1 3295:1 4812:1 4966:1 4978:1 5388:1
-1 	|BT| (S (S (S (ADVP (RB Additionally)) (, ,) (NP (NN co-treatment) (NN RV) (NN erlotinib)) (VP (VBD repressed) (NP (NP (NN expression) (JJ anti-apoptosis) (NN protein)) (, ,) (NP (NN survivin) (NN Mcl-1)))) (, ,)) (IN whereas) (NP (VBN promoted) (NN p53) (NN PUMA) (NN expression) (NN caspase) (CD 3) (NN activity)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 52:E02 906:D08.811.277.656.262.500.126.350.300 1042:Z01.107.757.284 1467:B01.050.150.900.649.147.354.630 1468:E01.370.386.700.485.750.275.650 1469:D12.644.360.075|ES| 2:1 4:1 12:1 19:1 115:1 372:1 399:1 466:1 862:1 1912:1 2229:1 2342:1 4068:1 4796:1 5312:1 5389:1 5390:1 5391:1 5392:1
-1 	|BT| (NP (NP (JJ Altered) (NN expression) (NN c-myc)) (, ,) (NP (NN p16) (NN p27) (NN rat) (NN colon) (NN tumor) (NN reversal) (JJ short-term) (NN treatment) (JJ chemopreventive) (NN agent))) |ET| |BS|51:C04.588.274.476.411.307.180 52:E02 203:G05.360.340.024.340.375.249.375 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 833:D27.505.696.706.018 849:G08.686.785.760.769.490.500|ES| 2:1 7:1 19:1 113:1 115:1 455:1 546:1 728:1 849:1 971:1 1124:1 1313:1 1946:1 3022:1 3770:1
-1 	|BT| (S (NP (NNP Assessment) (NN effect) (NN betaine) (NN p16) (NN c-myc) (NN DNA) (NN methylation) (NN mRNA) (NN expression) (NN chemical)) (VP (VBD induced) (NP (NN rat) (NN liver) (NN cancer) (NN model)))) |ET| |BS|111:D13.444.735.544 203:G05.360.340.024.340.375.249.375 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 366:G02.111.087.029.538.161 743:D02.092.877.883.077 838:E05.599.495|ES| 18:1 19:1 72:1 75:1 81:1 115:1 325:1 412:1 455:1 666:1 836:1 849:1 1313:1 2124:1 2636:1 5393:1
-1 	|BT| (NP (NP (DT Both) (NP (NNP BaA) (NNPS MeBaAs) (JJ similar) (NN effect) (NN expression) (NN cytochrome) (NN P450) (NN 1B1) (JJ aldo-keto) (NN reductase) (NN 1C9) (NN rat) (NN liver) (JJ epithelial) (NN WB-F344) (NN cell)))) |ET| |BS|75:A11.436 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 590:B01.050.050.199.520.760.200|ES| 19:1 75:1 94:1 96:1 115:1 127:1 332:1 836:1 849:1 2549:1 3276:1 3788:1 4678:1 5394:1 5395:1 5396:1 5397:1 5398:1
-1 	|BT| (S (NP (NNP CAPE) (CC plus) (NNP DEN)) (VP (VBD diminished) (NP (NP (NN expression) (NN cytochrome) (VBN involved) (NN DEN) (NN bioactivation) (NN CYP2B1)) (VP (ADVP (RB well)) (NP (NP (NN expression) (NN regulator) (JJ oxidative) (NN stress) (NN glutathione) (NN reductase)) (, ,) (NP (NN GST-kappa) (NN GST-theta)) (, ,) (NP (NN cell) (NN cycle) (NN regulator)) (NP (NN p53))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 7:D12.776 30:Z01.058.290.190.800 31:D08.811.520.224.800 155:G05.355.310 353:G04.299.134 716:G03.495.710 1470:D08.244.453.040.550 1471:D08.811.682.667.092 1472:D08.244|ES| 2:1 4:1 9:1 12:1 19:1 94:1 96:1 115:1 162:1 235:1 569:1 601:1 637:1 693:1 712:1 774:1 787:1 831:1 900:1 911:1 1719:1 1875:1 2332:1 2353:1 2522:1 2583:1 2744:1 3045:1 3146:1 3374:1 3788:1 4156:1 4350:1 4720:1 4888:1 5399:1 5400:1 5401:1 5402:1 5403:1 5404:1
-1 	|BT| (S (NP (NN Coexpression) (NN K-rasVal12) (NN TAgWt)) (VP (VBP produce) (NP (NN dysplasia)))) |ET| |BS||ES| 19:1 203:1 1565:1 5405:1 5406:1 5407:1
-1 	|BT| (S (NP (JJ Consistent) (NN finding) (, ,) (NN treatment) (NP (NP (NN protein) (NN kinase) (NN A)) (PRN (-LRB- -LRB-) (NP (NN PKA)) (-RRB- -RRB-))) (NN inhibitor)) (VP (VBD decreased) (NP (NN MMP2) (NN MMP9) (NN expression) (NN level) (JJ ADCY3-overexpressing) (NN cell)))) |ET| |BS|41:A11 52:E02 586:D08.811.277.656.300.480.205.360 1417:D08.811.277.656.300.480.205.352|ES| 2:1 4:1 10:1 14:1 19:1 69:1 94:1 115:1 202:1 249:1 380:1 470:1 546:1 927:1 3395:1 5408:1 5409:1 5410:1 5411:1
-1 	|BT| (S (NP (NN Curcumin)) (VP (VBZ sensitizes) (NP (NP (JJ human) (JJ colorectal) (NN cancer) (NN xenograft) (JJ nude) (NN mouse) (NN gamma-radiation)) (VP (VBG targeting) (NP (JJ nuclear) (JJ factor-kappaB-regulated) (NN gene) (NN product)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 88:B01.050.150.900.649.865.635.505.500.550.500 92:E04.936.764 93:A01.941.875 142:I01.880.604 210:D12.776.260.600 692:D02.455.326.146.485.222.222 816:G01.358.500.505.300 973:E05.393.335|ES| 9:1 17:1 18:1 19:1 36:1 52:1 265:1 266:1 616:1 675:1 1256:1 2062:1 3429:1 3430:1 3431:1
-1 	|BT| (S (NP (NN DEN) (NN treatment)) (VP (VP (VBD increased) (NP (NP (NN expression) (NN gene)) (VP (VBN associated) (NP (JJ oxidative) (NN stress) (NN glutathione) (NN reductase))))) (, ,) (NP (NP (NN gene) (VBN involved) (NN cell) (NN cycle) (NN regulation)) (PP (VBG including) (NP (NP (NN p53)) (, ,) (NP (VBN modified) (NN cytochrome) (NN P450))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 6:G05.360.340.024.340 52:E02 155:G05.355.310 716:G03.495.710 1079:D08.244.453 1259:G04.299.134.109 1471:D08.811.682.667.092|ES| 2:1 9:1 12:1 19:1 47:1 94:1 96:1 115:1 169:1 438:1 546:1 561:1 601:1 774:1 1875:1 2335:1 2522:1 2549:1 2583:1 2744:1 3788:1
-1 	|BT| (NP (NP (NP (NN DEN) (NN treatment) (VBN modified) (NN expression) (CD 665) (NN gene)) (, ,) (NP (NP (NN CAPE)) (CC plus) (NP (NN DEN))) (VP (VBD induced) (NP (NN change) (CD 1371) (NN gene))))) |ET| |BS|6:G05.360.340.024.340 52:E02 155:G05.355.310|ES| 2:1 9:1 19:1 115:1 200:1 412:1 546:1 1875:1 2332:1 2335:1 4888:1 5412:1 5413:1
-1 	|BT| (NP (NP (JJ Different) (NN mechanism) (JJ DEHP-induced) (JJ hepatocellular) (NN adenoma) (NN tumorigenesis) (JJ wild-type) (NN Ppar) (JJ alpha-null) (NN mouse))) |ET| |BS|29:B01.050.050.136.500.500 32:C04.697.098.500 33:C04.697.098 536:D12.776.826.239.500 911:D02.241.223.805.250 1194:C04.557.470.035.120|ES| 8:1 19:1 42:1 52:1 78:1 162:1 303:1 5384:1 5385:1 5414:1 5415:1
-1 	|BT| (S (NP (NP (NN DNA) (NN binding) (NN activity) (JJ nuclear) (NN factor) (NN kappa) (NN B)) (PRN (-LRB- -LRB-) (NP (NN NF-kappaB)) (-RRB- -RRB-))) (VP (VBZ transactivates) (NP (NP (NP (NN miR-155) (NN gene)) (ADJP (ADVP (RB significantly)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.002)))) (-RRB- -RRB-))) (JJ elevated) (NN liver) (JJ nuclear) (NN extract) (NN mouse)) (VBN fed) (NNP CDAA) (NN diet)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 198:D13.444.308 210:D12.776.260.600 595:G07.203.650.240 596:E02.642.249 663:C16.320.565.398.500.330.500 1473:D20.777.351|ES| 9:1 10:1 14:1 19:1 52:1 124:1 185:1 311:1 399:1 581:1 666:1 714:1 756:1 763:1 836:1 1254:1 1256:1 1487:1 1911:1 2191:1 2426:1 2496:1 3184:1 3750:1 5066:1
-1 	|BT| (FRAG (NP (NP (NP (NP (RB Early) (NN detection)) (JJ 2-amino-1-methyl-6-phenylimidazo) (-LRB- -LRB-) (JJ 4,5-b) (-RRB- -RRB-) (NN pyridine) (-LRB- -LRB-) (NN PhIP) (-RRB- -RRB-) (: -)) (VBN induced) (NN mutation)) (PP (IN within) (NP (NN Apc) (NN gene) (NN rat) (NN colon))))) |ET| |BS|18:G05.365.590 21:G05.360.340.024.340.375.249.050 46:A03.556.124.526.356 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 494:E01.390 744:D03.383.725|ES| 9:1 10:1 14:1 19:1 34:1 113:1 280:1 409:1 849:1 1023:1 2122:1 2638:1 2639:1 2640:1 2641:1 4135:1
-1 	|BT| (S (ADVP (RB Finally)) (, ,) (NP (NN PhIP)) (VP (VBD appeared) (NP (NP (NP (JJ carcinogenic) (NN XPA)) (PRN (-LRB- -LRB-) (: -) (: /) (: -) (-RRB- -RRB-))) (NN mouse) (JJ subtoxic) (NNS dos)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 279:D27.888.569.100|ES| 2:1 10:1 14:1 19:1 45:1 52:1 1929:1 2641:1 2653:1 3346:1 3836:1 5416:1 5417:1
-1 	|BT| (S (ADVP (RB Finally)) (, ,) (VP (VBP demonstrate) (NP (NP (JJ NSAID-mediated) (JJ nucleolar) (NN translocation) (NN RelA)) (VP (VBN associated) (NP (NP (NN downregulation) (JJ NF-kappaB-driven) (NN transcription) (NN NF-kappaB) (NN target) (NN gene)) (, ,) (NP (NN ICAM-1))))))) |ET| |BS|6:G05.360.340.024.340 66:F01.658.293 85:G02.111.087.225 209:G02.111.087.847 210:D12.776.260.600 463:C23.550.210.870 796:D27.505.696.663.850.014.040.500 1325:D12.776.395.550.200.450|ES| 2:1 9:1 19:1 160:1 169:1 250:1 487:1 502:1 595:1 714:1 1618:1 1929:1 4732:1 5418:1 5419:1 5420:1
-1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NP (JJ stress-associated) (NN hormone)) (, ,) (NP (NN isoproterenol)) (, ,)) (VP (MD could) (VP (VP (VB increase) (NP (NN expression) (NN level) (`` ``) (NN stem) ('' ''))) (: -) (S (NP (NP (JJ related) (NN protein)) (, ,) (NP (NN CD44)) (, ,) (NP (NNP Nanog)) (, ,) (NP (NN Rex-1)) (, ,)) (VP (VBP induce) (NP (NN chemoresistance) (JJ gastric) (NN cancer) (NN cell))))))) |ET| |BS|7:D12.776 41:A11 161:D06.472 309:A18.024.937 1474:D02.033.100.291.439|ES| 2:1 4:1 18:1 19:1 40:1 86:1 94:1 115:1 182:1 243:1 249:1 334:1 542:1 908:1 1106:1 1282:1 1581:1 3268:1 3269:1 5421:1 5422:1 5423:1 5424:1
-1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NN UDCA)) (VP (VBD inhibited) (NP (NP (NN Cox-2) (NN induction) (JJ Ras-dependent)) (: -) (NP (JJ independent) (NN mechanism))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 122:C14.280.383 737:D04.808.105.225.272.962|ES| 2:1 19:1 62:1 162:1 334:1 365:1 736:1 2631:1 5425:1 5426:1
-1 	|BT| (NP (NP (NP (JJ Genotype-phenotype) (NN correlation) (JJ murine) (NN Apc) (NN mutation)) (: :) (NP (NN difference) (NN enterocyte) (NN migration) (NN response) (NN sulindac)))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 251:D02.455.426.559.847.486.875 1475:A03.556.124.369.290 1476:E05.393.385|ES| 19:1 34:1 104:1 280:1 494:1 514:1 627:1 869:1 1674:1 3544:1 5427:1 5428:1
-1 	|BT| (S (NP (NN Hesperidin) (NN treatment)) (VP (VBD caused) (SBAR (S (NP (JJ significant) (NP (NP (NN up-regulation) (NN tumour) (NN suppressor) (NN phosphatase) (NN tensin) (NN homologue)) (PRN (-LRB- -LRB-) (NP (NN PTEN)) (-RRB- -RRB-))) (NN reduction) (NN expression) (NNP AOM)) (VP (VBD mediated) (NP (NN p-PI3K) (NN p-Akt))))))) |ET| |BS|52:E02 132:D02.172.080 142:I01.880.604 206:G05.360.340.024.340.375.249 378:D08.811.913.696.620.682.700.755 1035:D08.811.277.352.650 1290:D08.811.913.696.620.500 1477:D03.383.663.283.266.450.252.500|ES| 10:1 14:1 19:1 115:1 135:1 226:1 370:1 437:1 546:1 700:1 896:1 1011:1 1936:1 1994:1 2506:1 3619:1 3620:1 5429:1 5430:1 5431:1
-1 	|BT| (S (NP (NP (ADJP (RB Highly) (JJ metastatic)) (JJ hepatocellular) (NN carcinoma)) (VP (VBD induced) (NP (NP (JJ male) (NN F344) (NN rat)) (NP (VBN treated) (NN N-nitrosomorpholine) (NN combination) (NNS hepatocarcinogens))))) (VP (VBP show) (NP (JJ high) (NN incidence) (NN p53) (NN gene) (NN mutation)) (PP (IN along) (NP (JJ altered) (NN mRNA) (NN expression) (JJ tumor-related) (NN gene))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 18:G05.365.590 52:E02 104:C04.557.470.200.025.255 111:D13.444.735.544 149:G05.360.340.024.340.364.875.890 155:G05.355.310 434:E05.318.308.985.525.375 590:B01.050.050.199.520.760.200|ES| 9:1 12:1 19:1 34:1 115:1 178:1 303:1 304:1 325:1 337:1 412:1 429:1 530:1 693:1 849:1 1099:1 1402:1 1511:1 2666:1 2705:1 3185:1 3989:1 5432:1 5433:1
-1 	|BT| (NP (NP (NP (NP (NN Histogenesis) (NN role) (NN p53) (NN K-ras) (NN mutation) (NN hepatocarcinogenesis) (NN glyceryl) (NN trinitrate)) (PRN (-LRB- -LRB-) (NP (NN nitroglycerin)) (-RRB- -RRB-))) (JJ male) (NN F344) (NN rat))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 2:G05.360.340.024.340.375.249.385 15:F01.829.316.616 18:G05.365.590 590:B01.050.050.199.520.760.200 1478:D02.033.800.421.560|ES| 10:1 12:1 14:1 19:1 31:1 34:1 849:1 900:1 1121:1 1402:1 3185:1 5434:1 5435:1 5436:1 5437:1
-1 	|BT| (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN IBN-65)) (VP (VP (VBD induced) (NP (NP (NN apoptosis)) (NP (JJ down-regulating) (NNP Survivin)))) (, ,) (NP (NP (NN Bcl-2) (VBG up-regulating) (NN Bax)) (, ,) (VP (VBG leading) (NP (JJ sequential) (NN activation) (NN Caspase-3))) (, ,) (NP (NP (NN Caspase-9) (NN cleavage) (NN poly) (-LRB- -LRB-) (NN ADP-ribose) (-RRB- -RRB-) (NN polymerase)) (PRN (-LRB- -LRB-) (NP (NN PARP)) (-RRB- -RRB-)))))) |ET| |BS|39:G04.299.139.160 54:G05.360.340.024.340.375.500.791.150 86:D01.268.556.435 150:Z01.542.248.960 342:D12.644.360.075.718.400 351:A17.360 906:D08.811.277.656.262.500.126.350.300 1248:D08.811.913.400.725.115.690 1349:D08.811.277.656.262.500.126.550.900 1440:G04.299.134.220.250|ES| 2:1 10:1 14:1 19:1 89:1 158:1 225:1 244:1 394:1 412:1 468:1 639:1 1876:1 3097:1 3190:1 3779:1 4630:1 4810:1 4811:1 5247:1 5438:1 5439:1 5440:1 5441:1
-1 	|BT| (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN metformin)) (VP (VBD induced) (NP (NP (NN apoptosis) (NN OSCC) (NN cell)) (, ,) (VP (ADVP (RB significantly)) (VBG down-regulating) (NP (NP (JJ anti-apoptotic) (NN protein) (NN Bcl-2) (NN Bcl-xL)) (VP (VBG up-regulating) (NP (JJ pro-apoptotic) (NN protein) (NN Bax)))))))) |ET| |BS|39:G04.299.139.160 41:A11 54:G05.360.340.024.340.375.500.791.150 150:Z01.542.248.960 342:D12.644.360.075.718.400 351:A17.360 784:D02.078.370.141.450 1469:D12.644.360.075|ES| 2:1 4:1 19:1 89:1 94:1 124:1 158:1 244:1 412:1 468:1 1876:1 3097:1 4630:1 4814:1 5087:1 5230:1 5232:1 5442:1
-1 	|BT| (S (PP (IN In) (NP (NN HT-29) (NN cell))) (, ,) (NP (NN pterostilbene)) (VP (VBD reduced) (SBAR (S (NP (NP (NN protein) (NN level) (NN beta-catenin)) (, ,) (NP (NN cyclin) (NN D1) (NN c-MYC)) (, ,) (NP (JJ altered) (JJ cellular) (NN localization) (NN beta-catenin))) (VP (VBD inhibited) (NP (NN phosphorylation) (NN p65))))))) |ET| |BS|7:D12.776 23:D12.776.091.249 41:A11 122:C14.280.383 215:D12.644.360.262.150.100 792:A11.251.210.190.475 972:G02.111.087.677|ES| 2:1 4:1 19:1 60:1 94:1 244:1 249:1 365:1 452:1 625:1 693:1 743:1 744:1 2428:1 2484:1 2782:1 3074:1 3426:1 5016:1
-1 	|BT| (S (PP (IN In) (NP (NN HT-29) (NN cell))) (, ,) (NP (NN pterostilbene)) (VP (VBD reduced) (SBAR (S (NP (NP (NN protein) (NN level) (NN beta-catenin)) (, ,) (NP (NN cyclin) (NN D1) (NN c-MYC)) (, ,) (NP (JJ altered) (JJ cellular) (NN localization) (NN beta-catenin))) (VP (VBD inhibited) (NP (NN phosphorylation) (NN p65))))))) |ET| |BS|7:D12.776 23:D12.776.091.249 32:C04.697.098.500 33:C04.697.098 41:A11 46:A03.556.124.526.356 122:C14.280.383 158:D23.101 183:G04.299.233.750 215:D12.644.360.262.150.100 792:A11.251.210.190.475 972:G02.111.087.677|ES| 2:1 4:1 18:1 19:1 60:1 78:1 94:1 113:1 159:1 216:1 244:1 249:1 299:1 365:1 378:1 452:1 534:1 625:1 658:1 693:1 743:1 744:1 787:1 793:1 796:1 827:1 1474:1 1659:1 2250:1 2428:1 2430:1 2484:1 2782:1 3074:1 3426:1 5016:1
-1 	|BT| (S (PP (IN In) (NP (NN summary))) (, ,) (NP (VBN shown) (JJ first) (NN time) (NN UDCA)) (VP (VBD suppressed) (SBAR (S (NP (NN development) (NN tumor) (NN Ras) (NN mutation)) (VP (VBD blocked) (NP (NN activation) (NNP WT) (NN Ras))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 18:G05.365.590 322:G01.910 737:D04.808.105.225.272.962|ES| 2:1 7:1 19:1 34:1 35:1 225:1 237:1 244:1 307:1 490:1 816:1 1081:1 1775:1 1995:1 2631:1 2777:1
-1 	|BT| (FRAG (PP (IN In) (NP (NP (NNP AOM)) (ADVP (RB alone)))) (NP (NP (NN group)) (, ,) (NP (NN Cox-2)) (VP (VBD up-regulated) (SBAR (S (NP (ADJP (JJR >) (JJ 50-fold)) (NN tumor) (JJ normal) (NP (NN Ras)) (NN activity)) (VP (VBD enhanced) (NP (NN tumor) (JJ mutant) (JJ signaling-activated) (NN Ras)))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 69:G02.111.087.800 132:D02.172.080 142:I01.880.604 150:Z01.542.248.960 829:M01.686|ES| 2:1 7:1 19:1 62:1 118:1 241:1 244:1 385:1 399:1 811:1 1301:1 1466:1 1775:1 1994:1 2300:1 5443:1 5444:1
-1 	|BT| (FRAG (PP (IN In) (NP (NN study))) (, ,) (NP (VBN examined) (NN role) (NN Ras) (NN Cox-2) (NN inhibition) (NN UDCA))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 15:F01.829.316.616 43:F01.145.544 737:D04.808.105.225.272.962|ES| 2:1 19:1 31:1 62:1 103:1 131:1 244:1 324:1 1775:1 2631:1
-1 	|BT| (S (NP (NN Induction) (NN apoptosis) (NN pectenotoxin-2)) (VP (VBD mediated) (NP (NP (NP (NN induction) (NN DR4/DR5)) (, ,) (NP (NN Egr-1) (NN NAG-1))) (, ,) (NP (NN activation) (NN caspase) (NN modulation) (NN Bcl-2) (NN family) (JJ p53-deficient) (NN Hep3B) (JJ hepatocellular) (NN carcinoma) (NN cell))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 41:A11 44:F01.829.263 54:G05.360.340.024.340.375.500.791.150 104:C04.557.470.200.025.255 580:D12.776.260.158.500 1367:D08.811.277.656.262.500.126|ES| 2:1 19:1 89:1 94:1 97:1 158:1 225:1 303:1 304:1 437:1 736:1 1662:1 1945:1 2020:1 4498:1 4502:1 4561:1 4796:1 5236:1 5445:1
-1 	|BT| (S (NP (NN Induction) (NN SPARC)) (VP (VBD demonstrated) (NP (NN treatment) (JJ demethylating) (NN agent) (NN 5Aza-dC) (CD 5) (CD 7) (NN cell) (NN line)))) |ET| |BS|37:D12.776.157.125.715 94:A11.251.210 775:E02.760.058|ES| 19:1 82:1 94:1 264:1 546:1 578:1 728:1 988:1 1175:1 2020:1 5446:1 5447:1
-1 	|BT| (S (NP (NN IR-5) (NN bear) (JJ novel) (NN point) (NN mutation) (NN HER2/neu)) (VP (VP (VBZ corresponds) (SBAR (S (NP (NN L726I) (JJ ATP-binding) (NN pocket)) (VP (VBP correlate) (NP (NN log) (NN decrease) (NN sensitivity) (NN gefitinib)))))) (, ,) (NP (NP (VBD increased) (NN heterodimerization) (NN EGFR) (NN HER3)) (, ,) (NP (JJ impaired) (NN down-regulation))))) |ET| |BS|63:G05.360.340.024.340.375.500.791.295.305 85:G02.111.087.225 259:D12.776.395.240.150.500 438:G05.365.590.675 455:B01.050.150.900.649.147.890 1064:Z01.252.245.500.350 1065:D01.268.556.401|ES| 2:1 19:1 34:1 47:1 187:1 257:1 295:1 607:1 891:1 901:1 1740:1 2003:1 2121:1 3310:1 3505:1 4281:1 4955:1 4956:1 4957:1 4958:1 4959:1 4960:1 4961:1
-1 	|BT| (S (S (S (NP (NN Levamisole)) (VP (VBD increased) (NP (NNS ECs) (JJ integrin-dependent) (NN matrix) (NN adhesion)))) (PRN (, ,) (VP (VBD inhibited) (NP (NP (NP (NP (NN proliferation)) (PRN (-LRB- -LRB-) (NP (CD -70) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NP (VBN reduced) (NN expression) (NN survival) (NN factor) (NN clusterin)) (PRN (-LRB- -LRB-) (NP (CD -30) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NN endothelin-1) (PRN (-LRB- -LRB-) (NP (CD -43) (NN %)) (-RRB- -RRB-)))) (, ,) (NP (NN bcl-2) (PRN (-LRB- -LRB-) (NP (CD -34) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ endothelial) (NN NO-synthase)) (PRN (-LRB- -LRB-) (NP (CD -32) (NN %)) (-RRB- -RRB-))) (NP (NN pRb) (-LRB- -LRB-) (NN Retinoblastoma) (NN protein) (: :))) (NP (CD -89) (NN %))) (-RRB- -RRB-) (, ,)) (NP (NP (NP (NP (VBN increased) (NN growth) (NN arrest/death) (NN signal) (NN p21)) (PRN (-LRB- -LRB-) (NP (CD +73) (NN %)) (-RRB- -RRB-))) (NN bak)) (PRN (-LRB- -LRB-) (NP (CD +50) (NN %)) (-RRB- -RRB-))))) |ET| |BS|45:G07.700.320.249 54:G05.360.340.024.340.375.500.791.150 96:I03.784 122:C14.280.383 135:C23.550.260 871:D02.886.675.346 920:D12.776.543.750.705.408 1479:D12.776.260.704 1480:D08.811.682.664.500.772.750 1481:D12.644.276.400.225 1482:C23.550.355.274.840 1483:D12.776.395.207 1484:F04.570.200.583|ES| 2:1 4:1 10:1 14:1 19:1 47:1 102:1 104:1 115:1 151:1 185:1 274:1 299:1 365:1 369:1 452:1 753:1 859:1 1135:1 3088:1 3092:1 3093:1 3491:1 5448:1 5449:1 5450:1 5451:1 5452:1 5453:1 5454:1 5455:1 5456:1 5457:1 5458:1 5459:1 5460:1 5461:1 5462:1 5463:1
-1 	|BT| (S (NP (JJ Long-term) (JJ pharmacological) (NN MAP) (NN kinase) (NN inhibition) (NN MEK) (NN inhibitor) (NN PD98059)) (VP (VBD induced) (NP (NP (NN expression) (JJ terminal) (NN differentiation) (NN marker) (NN ITF)) (, ,) (NP (NN sucrase-isomaltase)) (, ,) (NP (NN mucin) (NN gene) (NN MUC2))))) |ET| |BS|6:G05.360.340.024.340 43:F01.145.544 71:D12.776.395.560.631 233:D08.811.913.696.620.682.700.565 234:D08.811.913.696.620.682.700.565 478:D08.811.913.696.620.682.700.567 849:G08.686.785.760.769.490.500 1045:D23.050.301.264 1059:H01.158.703 1485:D08.811.277.450.770 1486:V01.185.687|ES| 2:1 9:1 19:1 103:1 115:1 209:1 212:1 215:1 380:1 412:1 470:1 534:1 3707:1 4968:1 5110:1 5464:1 5465:1 5466:1 5467:1 5468:1
-1 	|BT| (S (NP (NNS METHODS) (: :)) (PP (IN In) (NP (NN study))) (VP (VBD used) (NP (NP (NN p53)) (VP (VBN mutated) (VP (VB knock) (S (NP (NP (NN colon) (NN cancer) (NN cell) (NN xenograft) (NN tumour) (NN study)) (NN role) (NN p53) (NN apoptosis)) (VP (VBD mediated) (NP (NNS diaminothiazoles))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 41:A11 92:E04.936.764 93:A01.941.875 168:E05.581|ES| 12:1 18:1 19:1 31:1 89:1 94:1 104:1 113:1 131:1 229:1 244:1 265:1 437:1 476:1 565:1 1011:1 5469:1 5470:1
-1 	|BT| (S (NP (NN MicroRNA-122)) (VP (VBZ inhibits) (SBAR (S (NP (JJ tumorigenic) (NN property) (JJ hepatocellular) (NN carcinoma) (NN cell)) (VP (VBZ sensitizes) (NP (NN cell) (NN sorafenib))))))) |ET| |BS|41:A11 104:C04.557.470.200.025.255 122:C14.280.383 184:D13.150.650.319 575:V02.050|ES| 19:1 94:1 303:1 304:1 615:1 841:1 1797:1 1809:1 2062:1 2063:1
-1 	|BT| (S (ADVP (RB Moreover)) (, ,) (NP (NN inhibition) (NN autophagy) (NN sensitization) (NN cisplatin) (NN NAC1) (NN knockdown) (NN inactivation)) (VP (VBN accompanied) (NP (NN induction) (NN apoptosis)))) |ET| |BS|39:G04.299.139.160 43:F01.145.544 390:G04.299.139.399 498:D01.210.375|ES| 2:1 19:1 89:1 103:1 464:1 622:1 736:1 1314:1 1317:1 1761:1 2137:1 2801:1 5471:1
-1 	|BT| (NP (NP (NP (NN Mutation) (NN analysis) (NN XPA)) (PRN (-LRB- -LRB-) (: -) (: /) (: -) (-RRB- -RRB-))) (NP (NP (NN mouse) (VBG carrying) (NN lacZ) (NN reporter) (NN gene)) (, ,) (S (VP (VBD indicated) (SBAR (S (NP (VBN observed) (NN toxicity) (NN PhIP)) (VP (MD might) (VP (VBD caused) (NP (JJ genotoxic) (NN effect) (JJ small) (NN intestine)))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 100:G05.360.340.024.686.545 218:A03.556.124.684 247:G01.374.676.530|ES| 2:1 9:1 10:1 14:1 19:1 45:1 52:1 75:1 261:1 288:1 356:1 641:1 661:1 750:1 798:1 850:1 1541:1 2406:1 2506:1 2641:1 3329:1 5416:1 5472:1
-1 	|BT| (S (NNS Mutations) (NP (NN codon) (NP (CD 13) (CD 117) (CC plus) (NP (JJ second) (NN exon) (NN insert)))) (VP (VBD contributed) (NP (CD 4) (NN %)) (NP (JJ total) (JJ H-ras) (NN frequency) (NN trichloroethylene) (NN tetrachloroethylene)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 113:C04.697.650 179:D01.248.497.300.459.700 335:D13.444.735.544.355 372:G05.360.340.024.340.137.232 1235:D02.455.526.439.939 1236:D02.455.526.439.880|ES| 19:1 319:1 369:1 1119:1 1247:1 1255:1 1410:1 1532:1 2347:1 3132:1 4416:1 4888:1 5473:1 5474:1 5475:1 5476:1 5477:1
-1 	|BT| (S (NP (NNP Nestin) (NN silencing)) (VP (ADVP (RB also)) (VP (VBD upregulated) (NP (NP (NN Axin) (, ,) (NP (NP (NN glycogen) (NN synthase) (NN kinase-3) (NN beta)) (PRN (-LRB- -LRB-) (NP (NN GSK-3beta)) (-RRB- -RRB-))) (, ,) (NP (JJ adenomatous) (NN polyposis) (NN coli) (PRN (-LRB- -LRB-) (NP (NN APC)) (-RRB- -RRB-))) (, ,)) (NP (NP (NN peroxisome) (JJ proliferator-activated) (NN receptor) (NN alpha)) (PRN (-LRB- -LRB-) (NP (NN PPARa)) (-RRB- -RRB-))))) (, ,) (VP (VBD downregulated) (NP (NP (NN beta-catenin)) (, ,) (NP (NN c-Myc)) (, ,) (NP (NP (NN cyclin) (NN D)) (NN MMP-7) (NN expression) (NNP CSC)))))) |ET| |BS|3:C04.557.470.035.215.100 21:G05.360.340.024.340.375.249.050 23:D12.776.091.249 536:D12.776.826.239.500 556:C11.768.175 937:D08.811.277.656.300.480.525.700.250 1046:D12.644.360.262.150 1047:D05.750.078.593.540|ES| 2:1 5:1 10:1 11:1 14:1 19:1 57:1 58:1 59:1 60:1 66:1 92:1 100:1 115:1 125:1 186:1 426:1 743:1 824:1 1801:1 1836:1 1887:1 1972:1 2592:1 3577:1 3650:1 3651:1 3652:1 3653:1 3654:1 3655:1
-1 	|BT| (S (ADVP (RB Notably)) (, ,) (NP (NN AcEGCG)) (VP (VP (VBD inhibited) (NP (NP (NN expression) (NN p53) (, ,) (NN p21) (, ,) (NN c-Myc) (, ,) (NN cyclin) (NN B)) (, ,) (NP (NN p-CDK1) (NN Cdc25A))) (ADVP (RB also)) (VP (VBD restored) (NP (NN activation) (NP (NP (JJ extracellular) (JJ signal-regulated) (NN kinase) (CD 1/2)) (PRN (-LRB- -LRB-) (NP (NN ERK1/2)) (-RRB- -RRB-)))))) (, ,) (VP (VBD decreased) (NP (JJ DMBA/TPA-induced) (NN increase) (NN tumor) (NN proliferation) (JJ mitotic) (NN index))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 116:D08.811.913.696.620.682.700.567.249.750 122:C14.280.383 212:E01.370.225.500.385.500 1487:D08.811.913.696.620.682.700.646.500.500.250 1488:D02.455.426.559.847.149.301 1489:D08.811.277.656.300.760.875 1490:D12.644.360.262.120|ES| 2:1 5:1 7:1 10:1 12:1 14:1 19:1 40:1 115:1 202:1 225:1 299:1 365:1 470:1 720:1 721:1 743:1 763:1 824:1 1135:1 1707:1 2798:1 4594:1 4812:1 4893:1 4966:1 5478:1 5479:1 5480:1 5481:1
-1 	|BT| (S (NP (NN OBJECTIVE) (: :)) (NP (NN FBXW7)) (VP (VBZ encodes) (NP (SBAR (S (NP (JJ substrate) (NN recognition) (NN component) (NN ubiquitin) (NN ligase)) (VP (VBZ degrades) (NP (NN target) (NN Notch1))))) (, ,) (NP (NN c-Jun)) (, ,) (NP (NN c-Myc) (NN cyclin) (NN E))))) |ET| |BS|415:F01.658.500 1458:D12.644.360.262.180 1491:F02.463.425.540.706 1492:D12.776.947.500 1493:D08.811.464|ES| 2:1 19:1 104:1 160:1 651:1 743:1 824:1 1021:1 1417:1 1686:1 2085:1 2211:1 3470:1 3757:1 5127:1 5482:1 5483:1 5484:1
-1 	|BT| (S (SBAR (IN Of) (S (NP (CD two) (NN gene)) (VP (VBP encode) (NP (NP (NN methionine) (NN adenosyltransferase)) (PRN (-LRB- -LRB-) (NP (NN MAT1Aand) (NN MAT2A)) (-RRB- -RRB-)))))) (, ,) (NP (NN MAT1A)) (ADVP (RB mainly)) (VP (VBD expressed) (NP (JJ adult) (NN liver)) (SBAR (IN whereas) (S (NP (NN MAT2A)) (VP (VBD expressed) (NP (JJ extrahepatic) (NN tissue))))))) |ET| |BS|6:G05.360.340.024.340 98:A10 119:M01.060.116 242:A03.620 574:D08.811.913.225.650|ES| 2:1 6:1 9:1 10:1 14:1 19:1 272:1 355:1 372:1 836:1 933:1 1429:1 1792:1 2050:1 2051:1 5485:1 5486:1 5487:1 5488:1 5489:1
-1 	|BT| (S (NP (RB Only) (NN 10-MeBaA)) (VP (VBD induced) (S (NP (NP (NN apoptosis) (NN accumulation)) (VP (VBN phosphorylated) (S (NP (NN p53))))) (, ,) (VP (MD could) (NP (NP (VBN associated) (NN induction) (JJ oxidative) (NN stress)) (, ,) (NP (JJ similar) (NN DMBA))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 716:G03.495.710 1488:D02.455.426.559.847.149.301|ES| 2:1 12:1 19:1 89:1 169:1 332:1 412:1 736:1 908:1 2120:1 2522:1 2583:1 4930:1 5490:1 5491:1 5492:1
-1 	|BT| (S (NP (PRP$ Our) (NN model)) (VP (VBZ predicts) (NP (NP (NP (NN 5FU) (NN sensitivity) (NN tumor)) (VP (VBN modified) (S (NP (NN aneuploidy)) (VP (VBG producing) (NP (NN copy) (NN number) (NN change) (NN TS) (NN allele) (CD one) (NN following)))))) (: :) (NP (NP (NN LOH)) (, ,) (NP (NN amplification)) (, ,) (, ,) (NP (VBN presented) (, ,) (NP (NN copy) (NN number) (NN change) (JJ due) (NN polysomy))))))) |ET| |BS|8:C04 77:G05.360.340.024.340.030 154:Z01.058.266.887 290:G05.365.590.029.530 560:D03.383.742.698.875.404 1494:C23.550.210.050|ES| 2:1 7:1 19:1 72:1 104:1 200:1 230:1 509:1 607:1 646:1 658:1 921:1 963:1 1004:1 1010:1 1751:1 2335:1 2851:1 3510:1 5493:1 5494:1 5495:1 5496:1 5497:1
-1 	|BT| (S (NP (PRP$ Our) (NN study)) (ADVP (RB also)) (VP (VBP demonstrate) (NP (VBN utilized) (NN DEN/PB) (NN protocol) (NNP WT) (NN C57BL/6) (NN mouse) (JJ select) (NN beta-catenin) (NN gene) (NN mutation) (NN hepatocarcinogenesis)))) |ET| |BS|18:G05.365.590 23:D12.776.091.249 593:B01.050.050.199.520.520.420|ES| 5:1 9:1 19:1 34:1 52:1 60:1 131:1 502:1 658:1 900:1 1182:1 1995:1 2192:1 3216:1 4183:1 5498:1
-1 	|BT| (S (NP (NN Panobinostat) (NN treatment)) (VP (VBD induced) (NP (NP (NP (NN downregulation) (NN EGFR)) (, ,) (NP (NN HER2)) (, ,)) (NN HER3) (ADJP (NN mRNA) (NN protein) (JJ transcriptional) (JJ posttranslational)) (NN mechanism)))) |ET| |BS|7:D12.776 52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 85:G02.111.087.225 111:D13.444.735.544 209:G02.111.087.847|ES| 2:1 4:1 19:1 162:1 187:1 188:1 325:1 412:1 546:1 559:1 595:1 4961:1 5499:1 5500:1
-1 	|BT| (FRAG (NP (NP (NP (NN PhIP) (NN diet)) (NP (ADJP (JJR >) (ADJP (CD 43) (NN week))) (NP (JJ present) (NN colon) (NN tumor) (JJ specific) (CD -1) (NN G) (NN mutation)))) (PP (IN within) (NP (QP (CD 5) ('' ')) (: -) (NN GGGA-3) ('' ') (NN sequence) (NN APC))) (: :)) (NP (NN gene))) |ET| |BS|3:C04.557.470.035.215.100 6:G05.360.340.024.340 18:G05.365.590 26:G02.111.570.080 51:C04.588.274.476.411.307.180 595:G07.203.650.240 596:E02.642.249|ES| 7:1 9:1 11:1 19:1 34:1 104:1 113:1 293:1 540:1 783:1 1307:1 1466:1 1489:1 2122:1 2191:1 2641:1 5501:1 5502:1 5503:1
-1 	|BT| (S (NP (NN Ras) (NN transformation)) (VP (VP (VBZ requires) (NP (NN Ras) (NN membrane) (NN anchorage))) (, ,) (VP (VBD promoted) (NP (NN farnesylcysteine) (NN carboxymethyl) (NN ester) (JJ additional) (NN sequence) (JJ specific) (NN Ras) (NN isoform))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 26:G02.111.570.080 238:D12.776.800 1344:A10.615 1495:D02.241.400|ES| 2:1 19:1 293:1 540:1 980:1 1384:1 1775:1 1912:1 2226:1 2331:1 3622:1 5371:1 5504:1 5505:1 5506:1
-1 	|BT| (FRAG (ADJP (NN Reentry) (JJ dependent)) (SBAR (IN upon) (S (NP (NN ability) (NN TAg)) (VP (VBP bind) (S (NP (NN pRB)) (VP (VBN associated) (NP (JJ p53-independent) (NN apoptosis)))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 385:F02.784.629.131 1479:D12.776.260.704|ES| 19:1 89:1 169:1 321:1 1300:1 1951:1 4857:1 5507:1 5508:1 5509:1 5510:1
-1 	|BT| (S (NP (NN RT-PCR) (NN Western) (NN blot) (NN assay)) (NP (VBN detected) (NN expression) (VBN known) (NN target) (NN miR-372) (JJ malignant) (NN tumor)) (VP (VBD found) (SBAR (S (NP (NP (NN Cyclin) (NN A1) (JJ Cyclin-dependent) (NN Kinase) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN CDK2)) (-RRB- -RRB-))) (VP (VBD downregulated) (NP (NN miR-372))))))) |ET| |BS|255:E05.196.401.143 272:E05.393.620.500.725 1365:D08.811.913.696.620.682.700.646.500.750 1496:D12.644.360.262.100.100|ES| 7:1 10:1 14:1 19:1 37:1 115:1 148:1 160:1 310:1 426:1 556:1 802:1 872:1 873:1 1007:1 1148:1 1543:1 2984:1 2992:1 4742:1 5511:1 5512:1
-1 	|BT| (S (NP (NN SAHA)) (VP (VBD mediated) (NP (NP (NN acetylation) (NN histone) (NN H3)) (ADVP (RB globally))) (, ,) (ADVP (RB well)) (, ,) (S (VP (VBN associated) (NP (NP (NP (NN p21)) (PRN (-LRB- -LRB-) (NP (NN WAF1)) (-RRB- -RRB-))) (NN promoter)))) (, ,) (NP (VBN measured) (NN chromatin) (NN immunoprecipitation)))) |ET| |BS|228:E05.978 1416:D12.776.660.470 1454:E05.393.170 1497:G02.111.087.019.052|ES| 2:1 10:1 14:1 19:1 83:1 169:1 437:1 503:1 787:1 789:1 1135:1 1346:1 4915:1 5145:1 5341:1 5513:1 5514:1 5515:1
-1 	|BT| (S (NP (NNP Saracatinib)) (VP (VBD enhanced) (NP (NP (NN effect) (NN lapatinib) (, ,) (NN EGFR/HER2) (JJ dual) (NN inhibitor)) (, ,) (NP (NN SNU216) (NN NCI-N87) (NN cell))))) |ET| |BS|41:A11 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 120:I01.409.418.750.600.480.150|ES| 2:1 19:1 75:1 94:1 380:1 385:1 2067:1 3347:1 5243:1 5516:1 5517:1 5518:1
-1 	|BT| (S (NP (JJ Short) (JJ G-rich) (JJ repetitive) (NN sequence)) (ADVP (RB previously)) (VBN identified) (NP (NNS hot-spots) (NN frameshift) (NN mutagenesis)) (VP (VBD induced) (NP (NP (JJ large) (NN variety) (NN carcinogen)) (VP (VBG belonging) (NP (JJ several) (NN family) (JJ widespread) (JJ environmental) (NN pollutant)))))) |ET| |BS|44:F01.829.263 279:D27.888.569.100 287:G05.365.590.265 612:G02.111.570.080.708 1359:G05.355.600 1498:G01.906.595.543 1499:D27.888.284 1500:C17.800.257|ES| 19:1 97:1 262:1 293:1 412:1 623:1 952:1 1527:1 2125:1 2264:1 3446:1 4073:1 4864:1 5519:1 5520:1 5521:1 5522:1 5523:1 5524:1 5525:1
-1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (NN DEHP)) (VP (MD may) (VP (VB induce) (SBAR (S (NP (NP (JJ hepatocellular) (NN adenoma)) (, ,) (NP (NN part)) (, ,) (SBAR (IN via) (S (NP (NN suppression) (NN G2/M) (NN arrest)) (VP (VBN regulated) (NP (NN Gadd45a) (NN caspase) (JJ 3-dependent) (NN apoptosis) (NN Ppar) (JJ alpha-null) (NN mouse))))) (, ,) (NP (NN gene))) (VP (MD may) (NP (VBN involved) (NN tumorigenesis) (JJ wild-type) (NN mouse)))))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 29:B01.050.050.136.500.500 32:C04.697.098.500 33:C04.697.098 39:G04.299.139.160 142:I01.880.604 536:D12.776.826.239.500 906:D08.811.277.656.262.500.126.350.300 911:D02.241.223.805.250 1194:C04.557.470.035.120|ES| 2:1 8:1 9:1 19:1 42:1 52:1 78:1 89:1 243:1 303:1 451:1 491:1 596:1 602:1 774:1 1537:1 1538:1 1664:1 2453:1 2528:1 3205:1 4796:1 5384:1 5385:1 5526:1 5527:1
-1 	|BT| (FRAG (NP (NP (DT The) (JJ chemopreventive) (NN effect)) (NP (NP (NNP Protandim)) (: :) (NP (NN modulation) (NN p53) (JJ mitochondrial) (NN translocation) (NN apoptosis) (NN skin) (NN carcinogenesis))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 33:C04.697.098 39:G04.299.139.160 463:C23.550.210.870 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 624:D27.505.696.706.018 785:A17.815|ES| 12:1 19:1 75:1 89:1 104:1 207:1 691:1 1618:1 1945:1 1946:1 2004:1 2319:1 5088:1
-1 	|BT| (NP (NP (NP (DT The) (ADJP (RB classically) (VBN recognized)) (NN target) (NN NSAID) (NN action)) (NP (NP (CD two) (NNS isoforms) (NP (NP (NN cyclooxygenase)) (PRN (-LRB- -LRB-) (NP (NN COX)) (-RRB- -RRB-))) (NN gene)) (, ,) (NP (JJ responsible) (NN prostaglandin) (NN production))))) |ET| |BS|6:G05.360.340.024.340 238:D12.776.800 796:D27.505.696.663.850.014.040.500 1119:D08.811.600.720.500 1501:D08.811.600.720 1502:D10.251.355.255.550|ES| 2:1 9:1 10:1 14:1 19:1 160:1 691:1 821:1 933:1 2013:1 2084:1 2132:1 2677:1 3180:1 3181:1 3237:1 4499:1 5528:1
-1 	|BT| (S (NP (DT The) (NNS data)) (VP (VBP suggest) (SBAR (S (NP (NP (NN TS) (NN copy) (NN number) (NN patient) (POS 's)) (NN tumor)) (VP (MD may) (VP (VBG dominating) (PP (JJ variable) (S (VP (VBG affecting) (NP (NN 5FU) (NN responsiveness))))))))))) |ET| |BS|8:C04 50:M01.643 154:Z01.058.266.887 560:D03.383.742.698.875.404|ES| 7:1 19:1 120:1 461:1 491:1 509:1 646:1 691:1 793:1 796:1 963:1 2530:1 3864:1 5493:1 5529:1 5530:1
-1 	|BT| (S (NP (NP (DT The) (JJ dysplastic) (NN epithelium) (NN K-rasVal12)) (CC x) (NP (NN TAgWt) (NN mouse))) (VP (VBP develop) (NP (NN neoplasm)))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 62:A10.272|ES| 19:1 52:1 173:1 648:1 691:1 1523:1 5406:1 5407:1 5531:1 5532:1
-1 	|BT| (S (NP (DT The) (NN effect) (NN folate) (NN transporter) (NN gene) (NN ablation) (NN colon) (NN carcinogenesis)) (VP (VBD evaluated) (NP (NP (CD 8) (CD 38) (NN week)) (JJ post-azoxymethane) (NN injection) (JJ wild-type) (JJ heterozygous) (NN mouse)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 157:G05.380.383 224:D03.438.733.631.400 225:E05.337 226:E02.319.267.530 227:D12.776.157.530|ES| 8:1 9:1 19:1 52:1 75:1 91:1 113:1 207:1 691:1 778:1 779:1 780:1 781:1 782:1 783:1 784:1 785:1 786:1
-1 	|BT| (NP (NP (NP (DT The) (JJ H-ras) (NN codon) (CD 61) (NN mutation) (NN frequency) (JJ tetrachloroethylene-induced) (NN tumor)) (NP (NP (ADJP (RB significantly) (JJR lower) (PRN (-LRB- -LRB-) (NP (CD 24) (NN %)) (-RRB- -RRB-))) (JJ combined) (NN control)) (NP (RB also) (CD two) (NN chemical))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 179:D01.248.497.300.459.700 194:G05.355.044.250.750 335:D13.444.735.544.355 1236:D02.455.526.439.880|ES| 5:1 7:1 10:1 14:1 19:1 34:1 117:1 124:1 164:1 289:1 369:1 691:1 933:1 1119:1 1247:1 2124:1 4338:1 5475:1 5533:1 5534:1
-1 	|BT| (NP (NP (DT The) (JJ K-rasVal12-augmented) (NN apoptosis) (JJ unrelated) (NN dysplasia)) (: ;) (S (NP (VBN enhanced) (NN apoptosis)) (ADVP (RB also)) (VP (VBD observed) (SBAR (S (NP (NN cycling) (JJ nondysplastic) (NNS enterocytes)) (VP (VBP produce) (NP (NN K-rasVal12) (NN TAg) (JJ COOH-terminal) (NN truncation)))))))) |ET| |BS|39:G04.299.139.160 1475:A03.556.124.369.290|ES| 5:1 19:1 89:1 203:1 217:1 261:1 385:1 691:1 1565:1 5362:1 5406:1 5508:1 5535:1 5536:1 5537:1 5538:1 5539:1 5540:1
-1 	|BT| (S (NP (DT The) (NN mutation) (NN spectrum) (JJ H-ras) (NN codon)) (NP (CD 61) (NN mutation)) (VP (VBD showed) (NP (NP (JJ significant) (NN decrease) (NN AAA) (NN increase) (NN CTA) (NN mutation) (JJ dichloroacetic) (NN acid)) (: -) (S (NP (JJ trichloroethylene-induced) (NN tumor)) (VP (VBN compared) (NP (JJ combined) (NN control))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 18:G05.365.590 179:D01.248.497.300.459.700 335:D13.444.735.544.355 1219:D02.241.081.018.214.500 1235:D02.455.526.439.939|ES| 7:1 19:1 34:1 40:1 50:1 132:1 135:1 164:1 289:1 295:1 691:1 1119:1 2249:1 4273:1 4336:1 5475:1 5533:1 5541:1 5542:1 5543:1
-1 	|BT| (S (NP (NP (DT The) (NN result) (NN show) (NN PhIP)) (NP (NP (ADJP (RB extremely) (JJ toxic)) (NN XPA)) (PRN (-LRB- -LRB-) (: -) (: /) (: -) (-RRB- -RRB-)) (NP (NN mouse)) (, ,))) (ADVP (RB even)) (VP (VBZ dos) (NP (RB 10-fold) (JJR lower) (VBN tolerated) (JJ wild-type) (NN C57BL/6) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 593:B01.050.050.199.520.520.420|ES| 2:1 8:1 10:1 14:1 19:1 45:1 52:1 101:1 117:1 429:1 691:1 1533:1 2192:1 2641:1 2653:1 5416:1 5544:1 5545:1 5546:1 5547:1
-1 	|BT| (S (NP (EX There)) (ADVP (RB also)) (NP (NP (JJR higher) (NN incidence) (NN K-ras) (NN activation)) (PRN (-LRB- -LRB-) (NP (CD 13) (NN %)) (-RRB- -RRB-))) (NP (JJ tetrachloroethylene-induced) (NN tumor)) (VP (ADVP (RB chemically)) (VBN induced) (NP (NN control) (NN tumor)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 434:E05.318.308.985.525.375 1236:D02.455.526.439.880|ES| 5:1 7:1 10:1 14:1 19:1 170:1 225:1 289:1 369:1 412:1 1121:1 1511:1 1532:1 2581:1 3217:1 4338:1
-1 	|BT| (S (NP (NP (DT These) (NN animal)) (NP (VP (VP (VBN reduced)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (NP (JJR <) (CD 0.05))) (-RRB- -RRB-))) (NP (JJ colonic) (NN RFC1) (NN mRNA)))) (VP (VBD exhibited) (NP (JJ 2-fold) (NN reduction) (NN plasma) (NN S-adenosylmethionine/S-adenosylhomocysteine)))) |ET| |BS|19:B01.050 46:A03.556.124.526.356 111:D13.444.735.544 175:J01.897.280.500.269 232:D02.886.030.676.180 657:A12.207.152.693|ES| 10:1 14:1 19:1 46:1 311:1 312:1 325:1 370:1 452:1 609:1 677:1 792:1 2400:1 3549:1 3849:1 5266:1 5267:1
-1 	|BT| (S (VP (DT These) (VBG finding) (VP (VBP suggest) (SBAR (S (NP (NP (NN exposure) (JJ dichloroacetic) (NN acid)) (, ,) (NP (NN trichloroethylene) (NN tetrachloroethylene))) (VP (VBZ provides) (S (NP (JJ selective) (NN growth) (NN advantage)) (ADVP (RB spontaneously)) (VP (VBG occurring) (NP (NP (NN mutation) (NN codon) (CD 61) (NNS H-ras)) (, ,) (NP (NN time)) (, ,) (NP (NP (JJ responsible) (JJ small) (NN number) (JJ unique) (JJ molecular) (NN lesion)) (VP (JJ suggestive) (NP (CC either) (NP (JJ random) (JJ genotoxic) (NN mode) (NN action) (JJ non-specific) (NN result) (JJ secondary) (NN DNA) (NN damage)))))))))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 18:G05.365.590 45:G07.700.320.249 113:C04.697.650 179:D01.248.497.300.459.700 322:G01.910 335:D13.444.735.544.355 526:G05.355.180 1219:D02.241.081.018.214.500 1235:D02.455.526.439.939 1236:D02.455.526.439.880 1503:E05.318.780.700|ES| 2:1 19:1 34:1 39:1 101:1 102:1 161:1 646:1 666:1 750:1 792:1 796:1 815:1 927:1 1081:1 1119:1 1131:1 1275:1 1469:1 1506:1 1737:1 1749:1 1848:1 1953:1 2013:1 2132:1 3329:1 4273:1 4419:1 5475:1 5476:1 5477:1 5533:1 5548:1 5549:1 5550:1 5551:1 5552:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (, ,) (NP (NP (ADVP (RB together)) (NP (NNP National) (NNP Toxicology) (NNP Program) (NN study)) (VP (VBG showing) (NP (NN evidence) (NN cytotoxicity) (NN genotoxicity) (NN oxazepam)))) (, ,) (S (VP (VBP suggest) (SBAR (S (NP (NN oxazepam)) (ADVP (RB preferentially)) (VP (VBZ promotes) (NP (NN cell) (VBG activating) (NN lesion) (NN ra)))))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 13:D01.339.387 41:A11 946:D27.888.569.213 1265:H01.158.891 1329:D03.438.079.080.070.663|ES| 2:1 19:1 38:1 94:1 101:1 131:1 298:1 792:1 796:1 1115:1 1131:1 1538:1 1958:1 2201:1 3317:1 3336:1 4491:1 4492:1 4493:1 4741:1 4819:1
-1 	|BT| (S (NP (NP (NP (NNP Thymidylate) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NN TS)) (-RRB- -RRB-))) (JJ important) (NN target) (NN 5-fluorouracil) (-LRB- -LRB-) (NN 5FU) (-RRB- -RRB-) (: -)) (VP (VBN based) (NP (NN therapy)))) |ET| |BS|52:E02 333:D01.045 560:D03.383.742.698.875.404 713:D08.811.913.555.500.862|ES| 10:1 14:1 19:1 66:1 130:1 160:1 509:1 902:1 2307:1 2895:1 3081:1 5493:1
-1 	|BT| (S (NP (NNS Tumors)) (VP (VBD isolated) (SBAR (S (NP (NP (NNS trout)) (VP (VBN treated) (NP (NP (NN DHEA)) (ADVP (RB alone))))) (VP (VBD contained) (NP (NP (NP (NN mutation) (NN Ki-ras)) (, ,) (NP (ADVP (RB primarily)) (NN codon) (CD 12) (-LRB- -LSB-) (CD 1) (-RRB- -RSB-) (NN G))) (: --) (NP (NP (JJR >) (DT A) (NN transition)) (, ,) (S (VP (VBG providing) (ADVP (JJ first)) (SBAR (S (NP (JJ suggestive) (NN evidence) (NN DHEA)) (VP (MD could) (NP (JJ genotoxic) (NN carcinogen)))))))))))))) |ET| |BS|8:C04 18:G05.365.590 52:E02 279:D27.888.569.100 335:D13.444.735.544.355 740:D04.808.054.079.429.625 1504:B01.050.150.900.493.817.750.825|ES| 2:1 19:1 34:1 38:1 53:1 69:1 98:1 241:1 552:1 816:1 908:1 1099:1 1119:1 1120:1 1373:1 1378:1 1466:1 1653:1 1970:1 2123:1 2125:1 2633:1 3025:1 3329:1 3720:1 4880:1 5549:1 5553:1 5554:1
-1 	|BT| (S (NP (NN UDCA)) (ADVP (RB significantly)) (VP (VBD inhibited) (NP (NP (NN Cox-2) (NN protein) (NN mRNA) (NN level)) (NP (NN tumor) (JJ normal) (NP (NN Ras)) (NN activity))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 7:D12.776 8:C04 111:D13.444.735.544 122:C14.280.383 737:D04.808.105.225.272.962|ES| 4:1 7:1 19:1 62:1 118:1 124:1 249:1 325:1 365:1 399:1 1775:1 2631:1
-1 	|BT| (S (S (S (VP (VBG Using) (NP (JJ genetic) (NN engineering)))) (, ,) (NP (VBN deleted) (NP (NP (JJ short) (JJ tandem) (NN repeat)) (PRN (-LRB- -LRB-) (NP (CD two) (NN repeat)) (-RRB- -RRB-))) (NN allele)) (VP (VBD retained) (S (NP (JJ long) (PRN (-LRB- -LRB-) (NP (CD three) (NN repeat)) (-RRB- -RRB-)) (NN allele)) (VP (VBP produce) (NP (JJ artificial) (NN LOH) (NN TS) (NN gene))))) (: ;)) (S (NN TS) (-LRB- -LRB-) (NP (CC +) (: /) (: -) (-RRB- -RRB-) (NN line)) (VP (VBD reduced) (NP (NP (NN TS) (NN protein) (NN expression) (JJ hypersensitive) (NN 5FU) (NN 5-fluoro-2)) ('' ') (: -) (ADVP (FW deoxyuridine) (FW vitro))) (NP (VBN compared) (JJ syngeneic) (NN control) (NN line))))) |ET| |BS|7:D12.776 30:Z01.058.290.190.800 31:D08.811.520.224.800 77:G05.360.340.024.340.030 154:Z01.058.266.887 290:G05.365.590.029.530 394:G02.111.570.080.708.800.500 560:D03.383.742.698.875.404 1505:G05.360.340.024.340.465 1506:E05.393.420|ES| 2:1 4:1 9:1 10:1 14:1 19:1 44:1 50:1 115:1 216:1 217:1 230:1 264:1 289:1 452:1 482:1 509:1 812:1 864:1 933:1 1001:1 1004:1 1565:1 1577:1 1719:1 2325:1 5493:1 5555:1 5556:1 5557:1 5558:1 5559:1 5560:1 5561:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD analyzed) (SBAR (S (NP (NP (NN matrilysin) (NN expression) (JJ benign) (JJ intestinal) (NP (NN tumor) (NN mouse) (JJ heterozygous) (NN ApcMin) (NN allele))) (PRN (-LRB- -LRB-) (NP (NN Min)) (: /) (NP (CC +)) (-RRB- -RRB-))) (VP (VBD found) (SBAR (S (NP (NN mRNA)) (VP (VBD induced) (NP (NP (NP (NN majority)) (PRN (-LRB- -LRB-) (NP (CD 88) (NN %)) (-RRB- -RRB-))) (NN adenoma)))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 17:C04.557.470.035 47:A03.556.124 77:G05.360.340.024.340.030 111:D13.444.735.544 157:G05.380.383 381:C04 937:D08.811.277.656.300.480.525.700.250|ES| 7:1 10:1 14:1 19:1 37:1 42:1 52:1 109:1 115:1 198:1 230:1 325:1 369:1 412:1 705:1 786:1 843:1 1168:1 1194:1 1288:1 3289:1 5562:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD explored) (NP (JJ tumor-promoting) (NN change) (JJ gestational) (JJ arsenic) (NN exposure) (NN focus) (NN Ha-ras) (NN mutation) (NN gene) (NN expression) (NN change)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 18:G05.365.590 155:G05.355.310 216:Z01.107.084.900.425 1158:D01.268.513.249 1266:G08.686.785.760.769|ES| 9:1 19:1 34:1 115:1 200:1 499:1 747:1 843:1 1431:1 1953:1 3776:1 3976:1 4106:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD demonstrated) (SBAR (S (NP (NN miR-122)) (VP (VBD suppressed) (NP (NP (JJ insulin-like) (NN growth) (NN factor) (CD 1) (NN receptor) (-LRB- -LRB-) (NN IGF-1R) (-RRB- -RRB-) (NN translation)) (VP (VBD sustained) (NP (NP (NP (NN glycogen) (NN synthase) (NN kinase-3) (NN beta)) (PRN (-LRB- -LRB-) (NP (NN GSK-3beta)) (-RRB- -RRB-))) (NN activity))))))))) |ET| |BS|145:G02.111.087.675.871 518:D08.811.913.696.620.682.725.400.185 809:L01.178.682.920|ES| 10:1 14:1 19:1 66:1 92:1 98:1 102:1 185:1 186:1 307:1 399:1 473:1 843:1 1175:1 1789:1 1847:1 1972:1 2093:1 3652:1 3653:1 5563:1
1 	|BT| (S (ADVP (RB Moreover)) (, ,) (NP (NN miR-221) (NN reduction)) (VP (VBD resulted) (NP (NN alteration) (JJ EMT-associated) (NN gene) (NN E-cadherin) (NN vimentin)) (NP (RB well) (ADJP (RB significantly) (JJR slower)) (NN xenograft) (NN tumor) (NN growth) (JJ nude) (NN mouse)))) |ET| |BS|8:C04 18:G05.365.590 45:G07.700.320.249 88:B01.050.150.900.649.865.635.505.500.550.500 92:E04.936.764 93:A01.941.875 820:D12.776.395.550.200.200 1527:D05.750.078.593.900|ES| 2:1 7:1 9:1 19:1 52:1 102:1 124:1 140:1 265:1 266:1 370:1 594:1 622:1 787:1 951:1 2267:1 5687:1 5688:1 5689:1
1 	|BT| (S (ADVP (RB Moreover)) (, ,) (NP (NN silencing) (NN IGFBP1) (NN gene)) (VP (VBD blunted) (NP (JJ emodin-induced) (NN inhibition) (NN cell) (NN growth) (NN cell) (NN cycle) (NN arrest)))) |ET| |BS|41:A11 42:G05.355.315.203.374 43:F01.145.544 45:G07.700.320.249 773:G04.299.134.109 1327:D12.776.157.420.250 1518:D02.455.426.559.847.117.159.205.400|ES| 2:1 9:1 19:1 94:1 100:1 102:1 103:1 601:1 602:1 622:1 5201:1 5613:1 5690:1
1 	|BT| (S (NP (JJ Natural) (JJ lipophilic) (NNS polyphenols)) (VP (JJ long-chain) (NP (NP (JJ polyunsaturated) (JJ fatty) (NN acid)) (PRN (-LRB- -LRB-) (NP (NNS PUFAs)) (-RRB- -RRB-))) (SBAR (S (ADVP (RB generally)) (VBP suppress) (NN Wnt) (: -) (NN NF-kappaB) (: -) (-LRB- -LRB-) (NP (JJ nuclear) (NN factor-kappa) (NN light-chain) (NN enhancer)) (VP (VP (VBD activated) (NP (NN B-cell))) (-RRB- -RRB-) (NP (JJ related) (NN pathway))))))) |ET| |BS|41:A11 56:D02.455.426.559.389.657.715 210:D12.776.260.600 425:G01.358.500.505.650 1528:D10.251.355|ES| 10:1 14:1 19:1 154:1 163:1 383:1 419:1 972:1 1256:1 1275:1 2070:1 2199:1 2441:1 2780:1 3364:1 4674:1 5265:1 5691:1 5692:1 5693:1 5694:1 5695:1 5696:1
1 	|BT| (NP (NP (NP (JJ Oral) (NN administration)) (SBAR (S (NP (NP (CD 50) (NN mg/kg) (NN CX-5461)) (VP (VBD induced) (NP (NN TP53) (NN expression) (NN activity)))) (VP (VBD reduced) (NP (NP (NP (NP (NP (NN proliferation)) (PRN (-LRB- -LRB-) (NP (NN MKI67)) (-RRB- -RRB-))) (NN invasion)) (PRN (-LRB- -LRB-) (NP (NN loss) (JJ ductal) (NN actin)) (-RRB- -RRB-))) (NN Hi-MYC) (NN tumor))))) (, ,) (NP (NP (NN PTEN-null)) (PRN (-LRB- -LRB-) (JJ low) (NN MYC) (-RRB- -RRB-))) (NP (NN tumor)))) |ET| |BS|8:C04 739:E02.319.267.100 1025:Z01.252.100.450 1026:Z01.252.474.651 1529:C16.131.831.512.400.410 1530:Z01.107.567.875.580.375 1531:D12.776.660.625.500 1532:D05.750.078.730.250|ES| 2:1 7:1 10:1 14:1 19:1 32:1 115:1 299:1 368:1 399:1 412:1 452:1 472:1 531:1 620:1 1018:1 2575:1 3585:1 5071:1 5697:1 5698:1 5699:1 5700:1 5701:1 5702:1
1 	|BT| (S (NP (NP (JJ Other) (NN study)) (, ,) (ADVP (RB therefore)) (, ,)) (VP (VBN performed) (NP (NN SW480) (NN cell) (NN silibinin)) (SBAR (S (ADVP (RB significantly)) (VP (VBD decreased) (NP (NP (NP (JJ beta-catenin-dependent) (NN T-cell) (NN factor-4)) (PRN (-LRB- -LRB-) (NP (NN TCF-4)) (-RRB- -RRB-))) (JJ transcriptional) (NN activity) (NN protein) (NN expression) (NN beta-catenin) (NN target) (NN gene) (NN c-Myc) (NN cyclin) (NN D1))))))) |ET| |BS|7:D12.776 23:D12.776.091.249 41:A11 155:G05.355.310 209:G02.111.087.847 215:D12.644.360.262.150.100 1533:D12.776.260.730.875 1534:C10.597.350.400 1535:D12.776.220.145|ES| 2:1 4:1 9:1 10:1 14:1 19:1 60:1 94:1 115:1 124:1 131:1 160:1 202:1 218:1 399:1 458:1 559:1 743:1 744:1 824:1 2635:1 3096:1 5210:1 5375:1 5703:1 5704:1 5705:1
1 	|BT| (S (NP (PRP$ Our) (NN observation)) (VP (VBP suggest) (NP (NP (JJ chemoprotective) (NN effect) (NN isorhamnetin) (NN colon) (NN cancer)) (VP (VBN linked) (NP (NP (JJ anti-inflammatory) (NN activity) (NN inhibition) (JJ oncogenic) (NN Src) (NN activity) (JJ consequential) (NN loss)) (VP (JJ nuclear) (NP (NP (NN beta-catenin)) (, ,) (NP (NN activity)) (NP (JJ dependent) (NN CSK) (NN expression))))))))) |ET| |BS|23:D12.776.091.249 43:F01.145.544 279:D27.888.569.100 429:N04.761.559.590.900 430:E05.581.249 686:D27.505.954.158|ES| 2:1 18:1 19:1 32:1 60:1 75:1 103:1 113:1 115:1 321:1 399:1 658:1 796:1 953:1 1256:1 1363:1 1477:1 2795:1 3672:1 3673:1 3674:1 3675:1 3676:1
1 	|BT| (S (NP (PRP$ Our) (NN result)) (VP (VBD showed) (S (NP (NNP ADN) (NN time)) (NP (ADVP (RB dependently)) (NP (VBD stimulated) (NP (NN WIF1) (NN gene) (NN protein) (NN expression) (NN MDA-MB-231) (NN cell))))))) |ET| |BS|6:G05.360.340.024.340 7:D12.776 41:A11 322:G01.910 759:D02.092.471.683.152.660 760:Z01.107.084.900.600 763:Z01.542.248.540|ES| 4:1 9:1 19:1 94:1 101:1 115:1 132:1 658:1 1081:1 2689:1 4854:1 5706:1 5707:1 5708:1
1 	|BT| (S (NP (NN Overexpression) (NN PinX1)) (VP (VBD resulted) (SBAR (S (NP (NP (NN G1/S) (NN phase) (NN arrest) (NN cell) (NN growth/proliferation) (NN inhibition)) (, ,) (NP (NN silencing) (NN PinX1))) (VP (VBD led) (NP (NP (NN acceleration) (NN G1/S) (NN transition)) (, ,) (NP (NP (NN cell) (NN growth/proliferation) (NN promotion)) (VP (VBG inhibiting/enhancing) (NP (NN telomerase) (NN activity)) (PP (IN via) (NP (NN p16/cyclin) (NN D1) (NN pathway))))))))))) |ET| |BS|43:F01.145.544 45:G07.700.320.249 86:D01.268.556.435 122:C14.280.383 183:G04.299.233.750 203:G05.360.340.024.340.375.249.375 212:E01.370.225.500.385.500 215:D12.644.360.262.150.100 1404:G02.111.087.222.880 1536:D08.811.913.696.445.308.300.750.750 1537:G01.595.560.107|ES| 2:1 19:1 94:1 100:1 103:1 383:1 399:1 552:1 594:1 596:1 602:1 668:1 744:1 2228:1 2337:1 2529:1 4430:1 5709:1 5710:1 5711:1 5712:1 5713:1 5714:1
1 	|BT| (S (NP (NP (NP (NN Overexpression) (NN progastrin)) (, ,) (NP (JJ nonamidated) (ADJP (RB incompletely) (VBN processed)) (NN product) (NN gastrin) (NN gene)) (, ,)) (VP (VBN shown) (VP (VBP induce) (NP (JJ colonic) (NN hyperproliferation))))) (VP (VBP promote) (NP (NP (JJ colorectal) (NN cancer) (NN mouse)) (, ,) (NP (NP (NN mechanism) (NN pathogenesis)) (VP (VBN defined)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 7:D12.776 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 46:A03.556.124.526.356 199:D06.472.317.413 200:D06.472.317.413|ES| 2:1 9:1 17:1 18:1 19:1 52:1 162:1 237:1 243:1 501:1 668:1 671:1 672:1 673:1 674:1 675:1 676:1 677:1 678:1 679:1 680:1
1 	|BT| (S (NP (NN PinX1)) (VP (VBZ suppresses) (NP (NN bladder) (JJ urothelial) (NN carcinoma) (NN cell) (NN proliferation)) (PP (IN via) (NP (NN inhibition) (NN telomerase) (NN activity) (NN p16/cyclin) (NN D1) (NN pathway))))) |ET| |BS|43:F01.145.544 203:G05.360.340.024.340.375.249.375 212:E01.370.225.500.385.500 215:D12.644.360.262.150.100 317:C04.557.470.200.430 933:A05.810.890 1536:D08.811.913.696.445.308.300.750.750|ES| 19:1 94:1 103:1 299:1 304:1 383:1 399:1 564:1 596:1 686:1 744:1 1078:1 5709:1 5713:1 5714:1
1 	|BT| (NP (NP (NN RNA) (NN interference) (JJ knockdown) (NN DRD2) (JJ pancreatic) (NN tumor) (NN cell)) (NP (NP (VBN reduced) (NN growth) (NN xenograft) (NN tumor) (NN mouse)) (, ,) (NP (NN administration) (NN DRD2) (NN inhibitor) (NN haloperidol) (NN mouse) (JJ orthotopic) (NN xenograft) (NN tumor))) (NP (VBD reduced) (JJ final) (NN tumor) (NN size) (NN metastasis))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 45:G07.700.320.249 92:E04.936.764 93:A01.941.875 113:C04.697.650 156:G05.355.315.203.374.790 362:D12.776.543.750.069.300.400.500 1069:D02.522.352.506 1538:C04.588.274.761|ES| 2:1 7:1 19:1 52:1 94:1 102:1 265:1 380:1 452:1 464:1 467:1 515:1 516:1 806:1 1210:1 2142:1 2575:1 3744:1 3884:1 5283:1
1 	|BT| (NP (NP (ADVP (RB Similarly)) (, ,) (NP (NP (NN HT-29) (NN colon) (NN cancer) (NN cell)) (, ,) (NP (NN isorhamnetin)) (VP (VP (VBD inhibited) (S (NP (JJ oncogenic) (NN Src) (NN activity) (NN beta-catenin) (JJ nuclear) (NN translocation)) (VP (VBG inducing) (NP (NN expression) (NN csk))))) (, ,) (NP (VBN verified) (NN RNA) (NN interference) (NN knockdown) (NN csk)))))) |ET| |BS|23:D12.776.091.249 122:C14.280.383 156:G05.355.315.203.374.790 279:D27.888.569.100 463:C23.550.210.870 792:A11.251.210.190.475|ES| 2:1 18:1 19:1 60:1 94:1 113:1 115:1 365:1 399:1 464:1 515:1 516:1 726:1 953:1 1256:1 1618:1 1864:1 2782:1 3673:1 3674:1 5715:1 5716:1
1 	|BT| (S (NP (NNP Simvastatin)) (VP (VP (VBD decreased) (NP (NN Skp2) (NN expression) (JJ transcriptional) (NN level))) (, ,) (VP (VBD resulted) (S (NP (NN p27) (NN accumulation)) (VP (VBG preventing) (NP (JJ proteasomal) (NN degradation))))) (, ,) (NP (NN effect) (VP (VBD mediated) (NP (NP (NP (NN signal) (NN transducer) (NN activator) (NN transcription) (CD 3)) (PRN (-LRB- -LRB-) (NP (NN STAT3)) (-RRB- -RRB-))) (NN inhibition)))))) |ET| |BS|43:F01.145.544 209:G02.111.087.847 250:E07.305.812 507:D12.776.157.743 754:D02.455.426.559.847.638.400.900 1281:D05.500.562.500 1293:G03.495|ES| 2:1 10:1 14:1 19:1 75:1 103:1 115:1 202:1 249:1 251:1 437:1 487:1 559:1 594:1 597:1 859:1 860:1 861:1 862:1 1124:1 1785:1 1937:1 2120:1 2961:1 4556:1
1 	|BT| (NP (NP (ADVP (RB Specifically)) (, ,) (NP (NP (NN coregulation) (NN kinase) (NN p38) (NN ERK)) (, ,) (NP (NN translation) (NN regulator)) (NP (NN 4EBP1)) (, ,) (NP (NP (NN transcription) (NN factor) (NN CREB)) (VP (VBG proliferating) (NP (JJ normal) (NN colon) (NN cell)))) (NP (VBD lost) (NN CRC))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 41:A11 46:A03.556.124.526.356 145:G02.111.087.675.871 166:D12.776.930 469:D08.811.913.696 809:L01.178.682.920|ES| 2:1 19:1 94:1 113:1 118:1 185:1 235:1 245:1 470:1 473:1 487:1 1666:1 2042:1 2865:1 5047:1 5717:1 5718:1 5719:1 5720:1
1 	|BT| (S (NP (NN Sulindac)) (VP (VBZ enhances) (NP (NP (JJ adenoviral) (NN vector)) (VP (VBG expressing) (NP (NP (NN mda-7)) (: /) (NP (NP (JJ IL-24-mediated) (NN apoptosis)) (NP (JJ human) (NN lung) (NN cancer)))))))) |ET| |BS|39:G04.299.139.160 55:B01.050.150.900.649.801.400.112.400.400 123:G05.360.337 251:D02.455.426.559.847.486.875 542:B04.280.030|ES| 18:1 19:1 36:1 89:1 328:1 362:1 810:1 1356:1 2965:1 5721:1 5722:1
1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (NNS data)) (VP (VBP suggest) (SBAR (S (NP (NN administration) (NN SHH) (NN inhibitor)) (VP (MD could) (NP (NP (JJ effective) (NN strategy) (VBP prevent) (JJ colitis-induced) (JJ colorectal) (NN carcinogenesis)) (, ,) (VP (ADVP (RB mainly)) (VBG targeting) (NP (NP (NN IL-6)) (NN signaling))) (, ,) (NP (VBG ablating) (NNS CSCs)) (, ,) (S (VP (VBG suppressing) (NP (NP (JJ oncogenic) (NN inflammation)) (, ,) (S (VP (VBG achieving) (NP (NN chemoquiescence)) (ADVP (RB ultimately))))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 53:C06.405.205.265 69:G02.111.087.800 201:D12.644.276.374.465.224 279:D27.888.569.100 525:C23.550.470 556:C11.768.175|ES| 2:1 17:1 19:1 195:1 207:1 380:1 616:1 733:1 793:1 796:1 908:1 953:1 1114:1 1537:1 1538:1 1639:1 1966:1 2250:1 2575:1 3064:1 3148:1 5488:1 5664:1 5723:1 5724:1 5725:1 5726:1 5727:1
1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)) (, ,) (S (VP (VBG finding) (NP (JJ demonstrative) (NN existence) (JJ novel) (NN pathway) (NN simvastatin)))))) (VP (VBZ induces) (NP (NP (NN G0/G1) (NN arrest)) (VP (VBG upregulating) (NP (NP (NN p21) (NN p27) (VBG activating) (NNP AMPK)) (VP (VBG inhibiting) (NP (NN STAT3-Skp2) (NN axis)))) (, ,) (ADVP (RB respectively)))))) |ET| |BS|82:D12.644.360.024.342.300 122:C14.280.383 259:D12.776.395.240.150.500 507:D12.776.157.743 579:A02.835.232.834.151.383 754:D02.455.426.559.847.638.400.900|ES| 2:1 19:1 214:1 371:1 383:1 602:1 880:1 891:1 927:1 1124:1 1135:1 1537:1 1538:1 1958:1 2089:1 2679:1 3140:1 4692:1 5666:1 5728:1 5729:1 5730:1
1 	|BT| (NP (NP (NP (DT The) (NN colon) (JJ epithelial) (NN cell) (NN line)) (NP (NP (NN NCM460) (NN colon) (NN cancer) (NN cell) (NN line) (NN HT-29) (NN Caco-2)) (VP (VBN exposed) (NP (NN P) (NN anaerobius) (NN control) (NNS bacteria))))) (: ;) (NP (NN cell) (VBN analyzed) (NP (NN immunoblot)) (, ,) (NP (NN proliferation)) (, ,) (NP (NP (JJ bacterial) (NN attachment) (NN analysis)) (VBN compared) (NN gene) (NN expression) (VBG profiling) (NN study)))) |ET| |BS|41:A11 46:A03.556.124.526.356 94:A11.251.210 718:E05.588.570 792:A11.251.210.190.475 802:E05.478.566.320 1286:E05.393.332 1539:B03|ES| 2:1 9:1 18:1 19:1 50:1 94:1 113:1 115:1 127:1 131:1 217:1 264:1 289:1 299:1 311:1 661:1 691:1 1168:1 2148:1 2782:1 2830:1 3102:1 3355:1 5731:1 5732:1 5733:1 5734:1 5735:1
1 	|BT| (S (NP (DT The) (JJ limonoid-treated) (NN xenograft)) (VP (VP (VBD exhibited) (NP (NP (JJ significant) (NN downregulation) (NN expression) (NN protein)) (VP (VBN involved) (NP (NP (NP (NN tumor) (NN cell) (NN survival)) (PRN (-LRB- -LRB-) (NP (NP (NN Bcl-2)) (, ,) (NP (NN Bcl-xL)) (, ,) (NP (NN c-IAP-1)) (, ,) (NP (NN survivin)) (, ,) (NP (NN Mcl-1))) (-RRB- -RRB-))) (, ,) (NP (NP (NN proliferation)) (PRN (-LRB- -LRB-) (NP (NN c-Myc) (NN cyclin) (NN D1)) (-RRB- -RRB-))) (, ,) (NP (NN invasion) (-LRB- -LRB-) (NN MMP-9) (, ,) (NN ICAM-1))))) (-RRB- -RRB-)) (, ,) (NP (NP (NN metastasis) (-LRB- -LRB-) (NN CXCR4) (-RRB- -RRB-)) (, ,) (NP (NP (NN angiogenesis)) (PRN (-LRB- -LRB-) (NP (NN VEGF)) (-RRB- -RRB-)))))) |ET| |BS|7:D12.776 8:C04 52:E02 54:G05.360.340.024.340.375.500.791.150 85:G02.111.087.225 92:E04.936.764 93:A01.941.875 108:G04.299.316 113:C04.697.650 175:J01.897.280.500.269 215:D12.644.360.262.150.100 586:D08.811.277.656.300.480.205.360 1204:D12.776.543.750.100.160.500.400 1325:D12.776.395.550.200.450|ES| 2:1 4:1 7:1 10:1 14:1 19:1 94:1 115:1 135:1 158:1 265:1 274:1 299:1 595:1 609:1 620:1 691:1 743:1 744:1 774:1 806:1 824:1 2066:1 2158:1 2229:1 2502:1 4220:1 4732:1 4814:1 5312:1 5736:1 5737:1
1 	|BT| (S (PP (DT These) (S (VP (VBG finding) (S (VP (VBP demonstrate) (NP (NN miR-137) (JJ crucial) (NN regulator) (NN cancer) (NN response) (NN doxorubicin) (NN treatment))))))) (, ,) (VP (VBP identify) (S (NP (NN miR-137) (ADJP (RB highly) (JJ promising)) (NN target)) (VP (VB reduce) (NP (JJ CAR-driven) (NN doxorubicin) (NN resistance)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 66:F01.658.293 136:D02.455.426.559.847.562.050.200.175 139:J01.937.500.100|ES| 2:1 18:1 19:1 160:1 235:1 420:1 494:1 502:1 546:1 599:1 626:1 792:1 832:1 927:1 1094:1 1517:1 2361:1 3690:1 5738:1
1 	|BT| (S (ADVP (RB Thus)) (, ,) (S (VP (VBG signaling) (NP (NN cascade) (, ,) (JJ positive) (ADJP (NN feedback) (NN loop) (JJ cooperative)) (NN interplay) (NN transcription) (JJ factors-induced) (NN expression) (NN IGFBP1) (NN gene)))) (VP (VBP contribute) (NP (JJ overall) (NN response) (NN emodin)))) |ET| |BS|69:G02.111.087.800 83:L01.143.283.425 155:G05.355.310 166:D12.776.930 696:V02.270.500 1327:D12.776.157.420.250 1518:D02.455.426.559.847.117.159.205.400|ES| 2:1 9:1 19:1 115:1 195:1 233:1 247:1 248:1 450:1 487:1 494:1 1691:1 2510:1 5274:1 5613:1 5739:1 5740:1 5741:1 5742:1
1 	|BT| (S (S (VP (TO To) (VP (VB confirm) (S (VP (VBG sensitizing) (NP (NN effect) (NN NAC1) (NN inhibition) (NN cytotoxicity) (NN cisplatin))))))) (VP (VBD attributed) (NP (NN suppression) (NN autophagy)) (, ,) (NP (NP (VBN assessed) (NN effect) (NN autophagy) (NN inhibitor) (NN 3-methyladenosine) (NN chloroquine)) (, ,) (NP (NP (NP (JJ small) (VBG interfering) (NNS RNAs)) (PRN (-LRB- -LRB-) (NP (NNS siRNAs)) (-RRB- -RRB-))) (VP (VBG targeting) (NP (NN beclin) (CD 1) (NN Atg5) (NN cytotoxicity) (NN cisplatin))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 43:F01.145.544 117:D13.150.650.700 390:G04.299.139.399 498:D01.210.375 946:D27.888.569.213 961:D03.438.810.050.180|ES| 2:1 10:1 14:1 19:1 75:1 98:1 103:1 380:1 616:1 750:1 828:1 1317:1 1761:1 2137:1 2453:1 3019:1 3044:1 3317:1 3378:1 3531:1 3823:1 5743:1 5744:1 5745:1 5746:1 5747:1 5748:1
1 	|BT| (S (NP (PRP We)) (VP (VBD observed) (NP (NP (JJ similar) (NN result) (JJ cellular) (NN model)) (JJ hepatocellular) (NN colon) (NN cancer)) (, ,) (S (VP (VBG indicating) (S (NP (JJ doxorubicin-sensitizing) (NN effect) (NN miR-137) (NN tumor)) (ADJP (JJ type-specific))))))) |ET| |BS|8:C04 41:A11 136:D02.455.426.559.847.562.050.200.175|ES| 2:1 7:1 18:1 19:1 72:1 75:1 101:1 113:1 261:1 303:1 332:1 420:1 843:1 2236:1 3074:1 5749:1 5750:1
